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IXSummary
The thesis was conducted during a period of six months at the University of
Santa Barbara in collaboration with prof. Eyal Dassau12, PhD, Francis J. Doyle
III12, PhD, Dale Seborg12,PhD . An abstract of the thesis was submitted for the
Diabetes Technology Meeting (DTM) Bethesda, Maryland 8th-10th November.
For people with type 1 diabetes mellitus, the pancreatic β-cell is completely
unable to produce insulin, and thus they require an insulin therapy for all their
life in order to survive. The common insulin therapy consists of multiple daily
insulin injections. In the last forty years, a new approach to provide continuous
insulin delivery has been introduced and it consists of three main elements: a
continuous glucose monitoring sensor, an insulin pump and a control algorithm.
This system is called Artiﬁcial Pancreas System (APS). The aim of this research
is to develop and evaluate a novel, model-based proportional-integral-derivative
(PID) control law for algorithmic insulin dosage computation.
The proposed PID design method is based on the Internal Model Control
(IMC) approach and a simple dynamic model proposed by van Heusden et al.
[1]. This third-order-plus-time-delay linear model has a single adjustable param-
eter that is personalized based on the subject’s TDI value. Thus, the model is
developed using readily available clinical information and does not require time-
consuming experimental tests. The resulting model is then approximated by a
second-order-plus time model which allows the controller settings to be calcu-
lated using the IMC design method. This design method has a single adjustable
1Department of Chemical Engineering, University of California, Santa Barbara, CA, USA
2Sansum Diabetes Research Institute, Santa Barbara, CA, USAparameter that allows the controller to be tuned to be more, or less, aggressively.
As a consequence, the three PID degrees of freedom are reduced to two: model
gain (K) and controller aggressiveness (τc).
The proposed controller design method is evaluated in silico study using
the FDA-approved UVA/Padova metabolic simulator. Ten simulated subjects
are used to determine a conservative value of the IMC design parameter, both in
the case of ﬁxed model gain and in the case of personalized gains, with a single
announced meal. Then the same subjects are used to evaluate the performance
considering changes of ± 50% in the insulin sensitivity. Subsequently, a diﬀerent
population of ten subject is used to perform a validation test with three unan-
nounced meals. The personalized PID controllers perform better than controllers
based on a ﬁxed model. Neither approach result in hypoglycemia for any of the
20 subjects.
Simulation studies have demonstrated that the proposed controller design
method is practical (no special tests required) and superior to controllers based
on non-personalized models.
XIIIntroduction
The term diabetes mellitus (DM) covers a group of common metabolic disorders
that cause an increase in blood glucose concentration, called hyperglycemia. In
the medical ﬁeld, distinct types of DM exist, and are caused by a complex interac-
tion between genetic, environmental and behavioral factors. The causes that lead
to hyperglycemia are diﬀerent, such as decrease of insulin secretion, decrease of
glucose use, and increase of glucose production [2]. Consequences for people who
suﬀer from this disorder are serious and dangerous, since DM compromises the
correct function of other metabolic pathways and causes haemodynamic changes,
leading to the damage of the eyes, kidney, and nerves [2]. In the USA, DM is
the main cause of renal failure, non-traumatic amputation of the lower limb and
blindness in adults. Even though all the kinds of DM are characterized by hyper-
glycemia, there are many diﬀerent types depending on the causes. Classiﬁcation
of DM is based on the pathogenesis processes that lead to hyperglycemia [2, 3].
Currently, there are two main categories of DM: type 1 and type 2. Type 1
diabetes mellitus (T1DM) is caused by the destruction of the insulin-producing β-
cells in the pancreas which leads to an insulin deﬁcit. It can be further divided into
subcategories. First, insulin-dependent type 1 is deﬁned by the damage immune-
mediated of the β-cells. Second, type 1 idiopathic is characterized by a deﬁcient
secretion of insulin by the pancreas, but without any proof of autoimmune de-
struction of β-cells [3].
Type 2 DM (T2DM), once known as not insulin-dependent, is characterized
by insulin resistance either by relative or absolute deﬁcit of insulin, causing a
heterogeneous set of diseases with the common factors of insulin-dependence at
diﬀerent levels, alteration in insulin secretion, and increased production of glucose[3].
During the last two decades, the presence of DM has signiﬁcantly increased.
In the occidental world the number of diabetes cases of a speciﬁc population over
a certain period exceeds 3% of the general population. Between 1976 and 1994
the spread of DM among adults in the USA increased from 8.9% to 12.3%. Fur-
thermore, the number of patients aﬀected by DM increased with the population
age, diﬀering from an incidence of 1.5% in individuals between 20 and 39 years to
20% in individuals over 75 years old. In the same way, alteration in postprandial
glycemia increased from 6.5% to 9.7% [3].
Numerous epidemiological studies highlight that the number of type 1 and 2
DM patients dramatically depends on geographic location, and revealing the in-
ﬂuence of diﬀerent genetic and environmental factors. Furthermore, recent studies
assert that the prevalence of T2DM is 10 times greater than T1DM in the Euro-
pean population and even more in Asia and Paciﬁc countries. Additionally, type
2 DM is likely to rapidly increase in the future because of the growing rate of obe-
sity and the decrease of physical activity, mostly in the industrialized countries
[3].
With regards to T1DM, it was found that the disease aﬀects subjects with
a particular genetic susceptibility. The prevalence of type 1 DM is higher in
northern countries: indeed Scandinavia shows the highest prevalence of type 1
DM and Finland shows an incidence of 35 cases per 100,000. On the other hand,
countries bordering the Paciﬁc have the lowest incidence, reaching incidence of
1-3 case per 100,000 in Japan and China. North Europe and USA shared the
same incidence of 8-17 cases per 100,000 [2].
T1DM generally starts in an infant-juvenile age, and it requires insulin ad-
ministration for the entire life of the patient, since the destruction of the β-cells
causes an absolute hormone deﬁciency. Because of the complete lack of insulin
secretion, T1DM can be considered to be the most critical type of diabetes and
this is why many studies are focused on it.
The most common therapy is insulin delivery by daily insulin injections, but
this approach does not reproduce the real dynamics of insulin secretion. In fact,
continuous insulin secretion is provided by the pancreas and is called basal insulin.
XIVIn addition, another dose of insulin is delivered after meal ingestion according
to the glucose concentration in the blood. Because of this biphasic behavior of
insulin secretion, new approaches that are able to mimic it are desired [3]. A novel
technique has been developed in the last four decades consisting of the use of an
insulin pump that provides continuous insulin administration.
The most critical part of this new approach lies in the development of a
feasible, robust and safe algorithm for insulin delivery which, along with the
pump and a glucose sensor, form the artiﬁcial pancreas system. The main aim of
this system is to improve patients’ lives by avoiding the dangerous situations of
hypo- and hyperglycemia [4].
XVChapter 1
The Articial Pancreas System
In this chapter brief physiological overview of the insulin production and the
characteristics of the diabetes mellitus are provided. Furthermore, the artiﬁcial
pancreas system is presented along with a description of its elements.
1.1 Physiology of the Pancreas
The Pancreas is an organ located in the abdomen with two diﬀerent functions:
exocrine and endocrine. The exocrine function is the production and secretion of
digestive enzymes; the cells of the pancreas which have this purpose are known as
pancreatic acini. The endocrine function is the production of several important
hormones such as insulin and glucagon, and cells involved in this secretion are
called isles of Langherans or pancreatic islets. Each distinct type of islet cell is
involved in the production of a diﬀerent hormone: the β-cells (or B cells) secrete
insulin, whereas α-cells (or A cells) provide glucagon. Another molecule that is
secreted by the islet cells is somatostatin which is produced by δ-cells (D cells).
This hormone has the capability of inhibiting the secretion of both insulin and
glucagon [5].
Insulin is a protein hormone composed of two chains: A and B, with 21 and
30 amino acids, respectively. Insulin’s task is to control organic metabolism since
it induces glucose to enter from the extracellular ﬂuid into cells. The insulin ef-
fect is felt by the target cells, which are insulin-dependent. These target cells are2 1. THE ARTIFICIAL PANCREAS SYSTEM
Figure 1.1: Insulin secretion by pancreatic islets and insulin path throughout the
blood before reaching the target cells [6].
mainly muscle cells (both cardiac and skeletal), adipose tissue cells and liver cells.
When insulin is secreted, it circulates throughout the blood and reaches the in-
sulin receptors of the cells as shown in Figure 1.1. Once the insulin hormone binds
to the cell receptors, they stimulate cytoplasmic vesicles containing the glucose
transporter, inducing them to reach the plasma membrane and then merge with
it. An increase in the number of glucose transporters in the plasma membrane
facilitates the glucose movement from the extracellular ﬂuid into the cells by fa-
cilitated diﬀusion. Plasma glucose concentration plays the most important role in1.2. TYPE 1 DIABETES MELLITUS 3
controlling the insulin secretion. Stimulation and activation of pancreatic β-cells
depends on changes in plasma glucose concentration. If plasma glucose concen-
tration increases, e.g after a meal, the β-cells are activated and the secretion of
insulin begins. On the other hand, a decrease in plasma glucose concentration
leads to removal of the insulin secretion stimulus [5].
Figure 1.2 provides a schematic representation of the glucose-insulin mecha-
nism. An increase in plasma glucose concentration causes a rapid stimulation of
insulin secretion and consequently an increase in plasma insulin concentration.
Afterwards, plasma insulin passes to the liver which degrades half of it, avoiding
liver glucose output since insulin inhibits conversion of the glycogen into glucose.
The other half of plasma insulin induces cells of the insulin-dependent tissues to
uptake glucose. As a result of the two diﬀerent actions of the insulin, one over the
cells and the other over the liver, the plasma glucose concentration is returned to
normal, around 80-140 mg/dl [5].
The antagonist of insulin is glucagon which has the function of reducing the
insulin concentration in the plasma, and therefore stops the insulin action and in
this way prevents hypoglycemia.
1.2 Type 1 Diabetes Mellitus
T1DM is an autoimmune disorder characterized by destruction of insulin-producing
β-cells in the pancreas. The consequence of this damage is the loss of endoge-
nous secretion of insulin that is essential to maintain euglycemia, causing life-
threatening hyperglycemia and keto-acidosys. As written above, the lack of in-
sulin secretion causes a loss in the ability to regulate glycemic levels in people
aﬀected by T1DM, thus making them suﬀer from long periods of hyperglycemia
without proper insulin management [3, 7].
This process usually develops in a few years, and hyperglycemia rises when
10% of the beta cells are still working. At that point, functional β-cells still exist,
but they are not able to supply a minimum level of insulin needed to maintain
euglycemia. Nevertheless, during this phase, glycemic control can be reached with
modest insulin administration. Unfortunately, this is a temporary phase and it4 1. THE ARTIFICIAL PANCREAS SYSTEM
Figure 1.2: Eﬀect of plasma glucose concentration over insulin secretion [5].
ends when all β-cells are completely destroyed by the autoimmune process [3, 2].
1.3 Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus is a disorder characterized by insulin resistance and
partial or absolute deﬁcit of insulin which is caused by progressive β-cell deteri-
oration. Most of the causes of this disease are genetic, it usually appears later in
life and it is associated with cardiovascular risk factors such as obesity. Indeed,
the majority of T2DM patients are obese with a high prevalence of fat in the
intra-abdominal area [3].
Typically, in T2DM there is a progressive reduction of β-cell secretion. Since1.4. INSULIN THERAPY 5
frequently T2DM patients show also a lack of willingness to follow dietetic and
behavioral therapy, it is often necessary to have more complex therapy scheme
before the insulin. Since the recourse to insulin therapy is often the ﬁnal stage for
T2DM and the disease typically emerges in older age, insulin therapy is mostly
focused on T1DM patients [3].
1.4 Insulin Therapy
The insulin hormone is synthesized by pancreatic β-cells and once in the blood, it
ﬂows throughout the hematic system and reaches the target organs: liver, muscles
and adipose tissue. In the target organs, insulin has the role of keeping suitable
glycemic levels either in the fasting phase (80 and 100 mg/dl), both nightly and
between meals, or in the pre-and postprandial phase (less than 140 mg/dl), af-
ter the meal intake. As a result of the complete lack of insulin in T1DM, the
liver overproduces glucose and prevents food glucose from being completely used.
The possibility to produce artiﬁcial insulin was discovered in 1920s and as a
result, a fatal disease turned into a treatable condition requiring life-long insulin-
replacement therapy [8]. It should be emphasized that the therapy goal is not
only survival, but also the prevention of chronic complications associated with
diabetes. Hypoglycemia can lead to a coma, and even death while hyperglycemia
can bring on several chronic diseases.
Insulin, like all proteins, cannot be taken orally because it would be degraded
by digestive enzymes, T1DM treatment consists of providing insulin either with
daily insulin injections or continuous insulin infusion (CII). Both therapy ap-
proaches require intravenous capillary glucose measurement in order to determine
the daily insulin dose for euglycemia [7].
With daily insulin injections, the insulin administration is provided in a subcu-
taneous way by either syringe or pen. Injection must be given in the subcutaneous
tissue where speciﬁc enzymes lie and where there are capillaries which are suit-
able for carrying insulin. If the insulin is injected too deeply, an intramuscular
administration would occur and the time of absorption would be modiﬁed causing
unpredictability of the absorption process [3].6 1. THE ARTIFICIAL PANCREAS SYSTEM
The CII therapy was introduced about twenty-ﬁve years ago and consists of
the use of a pump in order to provide continuous insulin administration. The use
of CII, along with continuous glucose sensing and a control strategy necessary to
bring a person with diabetes as close as possible to euglycemia, gives rise to a
closed-loop system known as the Artiﬁcial Pancreas (AP) [4].
1.5 Articial Pancreas System
The history of the Artiﬁcial Pancreas (AP) dates back to four decades ago when
closed-loop control was used to regulate blood glucose in individuals with T1DM
[7]. In general, the AP is a system that, on the basis of measurements of the level
of blood glucose, delivers the needed quantity of insulin with the use of an insulin
pump based on an algorithm. There are two main approaches for the implemen-
tation of the AP System(APS). The ﬁrst approach is the use of subcutaneous-
subcutaneous (sc-sc) in which an sc route for both glucose monitoring and insulin
delivery is adopted. On the other hand, an intravenous-intraperitioneal method
exists in which glucose monitoring is achieved by intravenous measurements and
intraperitioneal insulin is delivered [9].
In this paper an sc-sc body interface will be considered. The three main el-
ements of the APS are a subcutaneous glucose monitor (CGM), a continuous
subcutaneous insulin infusion (CSII) pump and the control algorithm which con-
trols the insulin dose. A schematic overview of this closed-loop system is shown
in Figure 1.3 [4].
Besides these three elements, other features are enclosed in APS such as a
safety algorithm, modeling, communication and interfaces. Hence, the APS is
often described as a puzzle and the primary piece of this puzzle regards safe
communication and data transfer between the three main elements listed above.
Naturally, the system provides a clear human interface in order to give all the
information needed to physicians and patients as well as a safety system using
interlocks, checklists and alarms [4].
In order to provide the right amount of insulin, it is sensible to understand and
take into account the dynamics of insulin delivery of an healthy pancreas. The1.5. ARTIFICIAL PANCREAS SYSTEM 7
Figure 1.3: APS: blood glucose concentration is detected by the CGM sensor and
on the basis of this information the control algorithm can calculate the amount of
insulin necessary to achieve the ﬁnal goal that is blood euglycemia. The calculated
insulin amount is delivered by the CSII [4].
pancreas of healthy subject continually produces a small basal amount of insulin
in order to keep glucose hematic levels stable. Furthermore, after each meal, an
insulin amount (bolus) is added to this basal insulin caused by the blood glucose
growth in the postprandial phase [3, 10]. As a result, in a healthy pancreas, the
response to a glucose clamp will show a biphasic behavior[11]. In the same way, a
subcutaneous pump should be able to provide the physiologic delivery of insulin
described above, releasing insulin in two ways:
• continuous for 24 hours through basal infusion, in order to hold glucose
blood value stable8 1. THE ARTIFICIAL PANCREAS SYSTEM
• intermittent during a postprandial phase using an insulin bolus in order to
control glucose blood after carbohydrate intake in a meal.
The insulin boluses and the basal insulin rate are based on an insulin-to-
carbohydrate ratio (I:C) and a correction factor (CF). These two parameters are
calculated through the use of measurements of the blood glucose concentration.
The I:C rate expresses the unit of insulin necessary to compensate for the amount
of carbohydrate (CHO), whereas the CF gives the unit of insulin necessary to
reduce the blood glucose concentration. The way in which the previous value is
obtained empirically is tailored to speciﬁc individuals. The combination of the
two values allows the calculation of the amount of insulin required in order to
control the blood glycemia at each given moment as a function of blood glucose
level and CHO intake [12].
However, control of glycemia is a rather complicated process which in healthy
subjects concerns various neural and hormonal inputs from the brain, gut, liver,
and pancreas; thus, the two values mentioned previously might not be suﬃcient
to achieve a good insulin administration. Moreover, the process is aﬀected by
various situations such as meal type, stress levels and exercise. As a consequence,
insulin requirements diﬀer throughout the day and from day to day; therefore, the
initial setting needs to be ﬁne-tuned to prevent insulin overdosing or under-dosing
[7, 4].
Currently, this biphasic behavior can be achieved with the use of only the
insulin pump, which provides bolus and basal insulin delivery. The new insulin
pumps can provide four diﬀerent ways to supply the bolus [10]:
a) only one infusion with the total amount of the insulin bolus
b) two infusions with half of the total amount of the insulin bolus for
each
c) two infusions, one with half of the total amount of the insulin bolus
delivered in the usual way, and the other delivered over a prolonged
period of time
d) one infusion of the total amount of insulin in the form of a basal rate.1.5. ARTIFICIAL PANCREAS SYSTEM 9
1.5.1 Continuous Subcutaneous Insulin Infusion (CSII)
Pump
Figure 1.4: Insulin Pump.[13]
The CSII pump is an electric-powered syringe pump which delivers rapid
action insulin. The rapid-acting human insulin, or an analog, is mainly used
for the CSII pump since their pharmacodynamic and pharmacokinetic behavior
mimics physiological insulin behavior. Moreover, this kind of insulin minimizes
the formation of crystals inside the plastic tubes of the pump, thus reducing the
possibility of obstructions. The syringe is linked to the subcutaneous abdomen
tissue by an infusion set in whose end a metal or Teﬂon needle is placed. The
abdomen tissue is the ideal place for insulin infusion since the uptake is more
rapid and constant in that region [10].
Technological progress in coming years will further improve instrument per-
formance, leading to a reduction in weight and size (new models measure 5 × 8.6
× 2 cm and weight about 100 g). Over the years, the metal needle of the infusion
set has been replaced by a Teﬂon catheter which is introduced into the body by
a metal runner, immediately removed after the catheter insertion.
A schematic ﬁgure of the main parts of the pump is provided in Figure 1.5.
It consists of the main device which encloses a disposable reservoir of insulin
(300 units), a mechanism for the delivery of insulin at diﬀerent rates, and a
microcomputer which executes the program using batteries [10].10 1. THE ARTIFICIAL PANCREAS SYSTEM
Figure 1.5: Insulin pump components [10].
It is important to emphasize that the main issue in the use of a CSII pump
is the delay in action since the subcutaneous insulin absorption needs time. In
particular, after the injection of a regular subcutaneous bolus, insulin takes up
to 120 min to be absorbed and able to have peak glucose. From a safety point of
view, this slow insulin absorption may cause insulin under-delivery which, if not
controlled, can lead to ketoacidosis [14].
Another limit of the CSII therapy is the need for training patient. This therapy
has best results with well-trained patients who are motivated in learning and self-
monitoring [5]. On the other hand, patients with a low willingness might impair
the required management of pump treatment. Moreover, an external pump can
be uncomfortable for the patient, and therefore the quality of life may worsen
because of this choice of therapy [3].
1.5.2 Continuous Glucose Monitoring (CGM)
Continuous glucose monitoring techniques were ﬁrst introduced about ten years
ago in order to provide a retrospective analysis of glucose proﬁles. Afterwards,
real-time device were developed that gave on-line readings of blood glucose con-
centration [14]. The ﬁrst commercially available continuous glucose monitoring
device was the MiniMed R ⃝ continuous glucose monitoring system (CGMS; Min-
iMed Inc., Sylmar, CA). It was composed of a sterile, disposable subcutaneous
glucose sensor which collected measurements of glucose concentration in the in-1.5. ARTIFICIAL PANCREAS SYSTEM 11
Figure 1.6: A CGM device [15].
terstitial ﬂuid. The sensor was connected via external electrical cable to a small
monitor and information was sent to the control algorithm usually via a wireless
system. The glucose concentration was measured every 10 s and an average value
was stored and provided to the controller every ﬁve minutes for a total of 288
measurements each day [15].
Since CGM information is the basis of the control algorithm of the AP system,
a good knowledge of CGM limitations and issues is essential. First, it should be
taken into account that the glucose concentration that is detected is interstitial
and signiﬁcantly diﬀerent from the actual blood glucose when conditions change
quickly. In order to reduce this diﬀerence, a device calibration is required with
several daily blood glucose samples. Studies indicate that relevant improvements
in CGM accuracy can be achieved by calibrating the sensor during periods of
relative glucose stability [14]. A second issue which inﬂuences the CGM accuracy
is the time lag due to the blood-to-interstitial glucose transportation and the
sensor processing time.
Moreover, errors from transient loss of sensitivity and random noise complicate
issues further. Obviously, the main aim is to avoid all these complications since12 1. THE ARTIFICIAL PANCREAS SYSTEM
accurate readings of the CGM are fundamental for the closed-loop controller.
To this end, ﬁltering, denoising and artifact rejection in CGM data should be
performed. Even though these issues may inﬂuence CGM accuracy, the device
provides frequent sampled data, e.g every 5-10 min, allowing for the successful
development of the APS [14].
1.5.3 Control Algorithm
The control algorithm plays a fundamental role in the artiﬁcial pancreas. Be-
cause of its great importance, many studies have been conducted over the years
developing various algorithms. However, two main types of algorithms have been
identiﬁed as the most attractive: proportional-integral-derivative (PID) control
[16, 17, 18] and model predictive control (MPC)[7, 1].
Figure 1.7: Closed-loop of the APS [11].
PID algorithms use three components in order to administrate insulin: the
deviations from a target glucose level (the proportional component), the area
under the curve between the measured and the target glucose level (the integral
component) and the rate of change in the measured glucose levels (the derivative
component). The PID controller is merely reactive since it responds to changes1.5. ARTIFICIAL PANCREAS SYSTEM 13
in glucose concentration after their occurrence. As a result, the inherent delays
and inaccuracies in both glucose sensing and insulin delivery may lead to an
unstable system if the controller is too aggressive. In general, a good controller
design should account for time delay in measurements and insulin delivery. How-
ever, if the controller response is too slow, postprandial glucose peaks cannot
be appropriately reduced [8]. On the other hand, MPC algorithms, compute the
insulin delivery by minimizing the diﬀerence between predicted glucose concen-
trations and the target glucose levels over a prediction horizon of 1.5 to 3 hours,
or longer. Prediction of the current and future insulin infusion rates, and thus
the corresponding predicted glucose amount, is based on a model of the patient
metabolic system. Since the MPC algorithm predicts the level of glucose in the
blood due to the eﬀect of the insulin administrated and the disturbances, e.g;
meals and physical activity, it is called proactive. This controller design is well-
suited to compensate for time delay due to subcutaneous insulin delivery and
subcutaneous glucose measurements [14, 8].
Despite the remarkable advantages that MPC algorithms show, glucose clamp
studies illustrate a biphasic insulin response and in the same manner PID can
also provide this type of response. This observation suggests that the β-cells’
behavior can be replaced with a PID controller. It is important to underline
that any controller with integral action will respond in a biphasic way. For this
reason, new methods of control algorithms have been introduced, e.g; Internal
Model Control (IMC). This type of controller is related to the PID controller
since it can be rearranged to be equivalent to a PID controller, but with less
tuning parameters, this is why it can be considered as a conventional tuning
methods for the PID controller [19].
However, with for IMC approach the model chosen to represent the insulin-
glucose dynamics is very important since the controller performance depends on
it.Chapter 2
Control Algorithms and Models
In this chapter a brief theoretical introduction to the PID controllers and the
IMC method is provided. Furthermore, an overview of the most common model
for the glucose/insulin dynamic are presented, focusing on the control-relevant
models which are the type used for the controller implementation.
2.1 Control Algorithms
The two main controller algorithms utilized in the Artiﬁcial Pancreas design are
considered with a particular attention paid to the PID controller, since it is the
controller that is evaluated in this work.
2.1.1 Model Predictive Control
The MPC is basically composed of three main elements: the model, the cost func-
tion and the constraints.The model allows the prediction of future states of the
outputs with information about the current state, future values of the manipu-
lated variables and future values of the measurable or predictable disturbances.
The performance of the closed-loop control is calculated by minimizing the cost16 2. CONTROL ALGORITHMS AND MODELS
function [20, 11]. The cost function is usually a weighted quadratic form [20]:
J(k) =
N ∑
i=0
(q(ysp(k + i) − y(k + i))
2 + (u0(k + i) − u(k + i))
2) (2.1)
y : glucose concentration
u : insulin infusion rate
q : weight
(2.2)
which penalize future deviations of the output (ym) from the set point (ysp) and
it can also include also a quadratic penalty on future control actions which can
be either the diﬀerence between u and a reference u0 or the incremental changes,
∆u(k) = u(k)−u(k −1) [20]. Constraints are applied over the variables, e.g over
the insulin administration rates by the pump and over the glycemia which has to
be in an admissible rates.
u(k)min ≤ u(k) ≤ u(k)max (2.3)
∆u(k)min ≤ ∆u(k) ≤ ∆u(k)max (2.4)
y(k)min ≤ y(k) ≤ y(k)max (2.5)
In Figure 2.1 a schematic overview of the basic idea about MPC is provided.
The two sub-ﬁgures are divided into past and future. The top sub-ﬁgure shows
the history of both glucose (y) and insulin (u) before the current time tk. At
each time value of tk the sequence of current and future insulin delivery rates
is computed by optimizing the object function subjects to the constraints over a
future horizon of P time steps. Than, only the ﬁrst control move out of M steps is
actually implemented, resulting in a new glucose value y(k + 1) at the next step
t(k + 1). The next step, at the time tk shown in the bottom sub-ﬁgure, consists
of the translation of the predictions, the control horizons and, repetition of the
same procedure, always implementing only the ﬁrst control move [20, 11]. An
advantage of this optimization-based approach is that the control objective can
be weighted on the basis of the glucose hyperglycemia or hypoglycemia conditions
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Figure 2.1: MPC prediction scheme. The top portion shows the MPC algorithm
at time tk and the future model prediction both of the glucose and the insulin.
The bottom portion shows the results of glucose and insulin after the ﬁrst move
of the previous prediction has been implemented and the new model prediction
computed at the time tk+1.[11]
2.1.2 Continuous PID Control
The proportional-integral-derivative (PID) controller is the predominant feedback
control algorithm in the process industries [19]. In general, the feedback control
algorithm aims to minimize the diﬀerence between the desired output value (set-
point) and the actual output measured. This diﬀerence is called the error and
it will be equal to zero only in the case in which the actual output, that is the
measured level of glucose, is exactly equal to the set point. In this case, the system18 2. CONTROL ALGORITHMS AND MODELS
will be perfectly controlled [19].
e(t) = ysp(t) − ym(t) (2.6)
e(t) : error signal
ysp(t) : set point
ym(t) : measured value of the controlled variable (glucose concentration)
As the name suggests, PID controller is composed of combination of three
control modes, and each of them operates a speciﬁc action over the error in order
to compute the control variable.
Proportional Control
The ﬁrst contribution is proportional to the error; therefore it is called propor-
tional control mode.
u(t) = ¯ u + Kce(t) (2.7)
u(t) : controller output (insulin infusion rate)
¯ u : bias (steady-state) value
Kc : controller gain
The proportional controller has two advantages:
1. By tuning the controller gain, it is possible to make the controller more or
less aggressive.
2. The sign of Kc determines whether the controller output increases or de-
creases when e(t) increases.
The value of ¯ u is set so that the controller output is equal to its nominal steady-
state when the error is zero. For the artiﬁcial pancreas control applications, the
Kc dimension is (pmol/min/mg/dl) since u is the insulin amount and ¯ u is the2.1. CONTROL ALGORITHMS 19
basal insulin Ib. The basal insulin brings the subject to their glucose steady state
which can be diﬀer from the set point. A disadvantage of a controller with only
the proportional mode is the presence of the steady-state error called (oﬀset) after
changing in the set point or a prolonged disturbance. However, this oﬀset can be
eliminated by the introduction of the integral mode [19].
Integral Control
The integral control contribution is proportional to the integral of the error over
time:
u(t) = ¯ u +
1
τI
∫ t
0
e(t
∗)dt
∗ (2.8)
τI : integral time
Its most important advantage is elimination of the oﬀset. u changes as far as the
e(t∗) is diﬀerent to zero, bringing the steady-state error equal to zero.
When a set point change or a signiﬁcant disturbance perturbs the system, it
is possible that the controller output reaches an upper or lower limit. In this case,
even though the error is not equal to zero, the controller action cannot increase.
This situation is called controller saturation.
Furthermore, at saturation, the error usually can still be not equal to zero, and
the integral term continues to increase without producing any eﬀect on the out-
put variable. This phenomenon is referred to as reset windup on integral windup
[19]. In the APS, the CSII pump plays the role of the control action actuator and
it is subject to a maximum delivery constraint; thus this actuator bound should
be considered while implementing a integral controller.
Derivative Control
The derivative control contribution has the aim to anticipate the error signal
variations by taking into account its rate of change. The ideal derivative action20 2. CONTROL ALGORITHMS AND MODELS
is:
u(t) = ¯ u + τD
de(t)
dt
(2.9)
τD : derivative time
Since the control output will be equal to the nominal value only with a constant
error, derivative control is never used alone [19].
Proportional-Integral-Derivative Control
Figure 2.2: Block diagram of the parallel form of PID control [19].
The combination of the three components described above gives rise to the
popular PID controller. The control law of the PID parallel form is given by[19]:
u(t) = ¯ u + Kc
[
e(t) +
1
τI
∫ t
0
e(t
∗)dt
∗ + τD
de(t)
dt
]
(2.10)
u
′(t) = u(t) − ¯ u (2.11)
And the corresponding controller transfer function is:
U′(s)
E(s)
= Kc
[
1 +
1
τs
+ τDs
]
(2.12)
U
′(s) : u’(t) Laplace transform
E(s) : e(t) Laplace transform2.1. CONTROL ALGORITHMS 21
A PID control disadvantage is the so-called derivative kick. It is a momentary
large value of the derivative term due to a fast change in the set point and thus
in the error change rate. The undesirable spike can be avoided by setting ysp=0
in the derivative terms [19].
2.1.3 Intuitive Description of PID Control Action
Considering the three PID components from a physical point of view, it is possible
to understand the role that each component plays in determining the insulin
infusion rate.
The proportional element provides a contribute only when the glucose con-
centration is above or below the set point value. When the glucose is at the set
point, the proportional contribution does not aﬀect the output [21].
The integral term changes value when either the glucose concentration is above
or below the set point. Since the integral contribute is always active unless e(t) =
0, it ensures that target is always achieved when the system is at the steady-state
[21].
The derivative component increases when glucose rate of change is rising and
decreases when it is falling. As a results, each detection of glucose rate of change
leads to a change in insulin delivery independent of the current glucose level [21].
Figure 2.3 shows the response of the three PID modes of Steil et al. [21] to
a hyperglycemic clamp.[21] The blue area shows the proportional contribution
(P(n)), the green area represents the integral action (I(n)) and the pink area
shows the derivative component (D(n)).
Stability
It is essential that the closed-loop system is stable which means that the output
response is bounded for all bounded inputs [19].
Fortunately, the desired control system behavior can be achieved changing
speciﬁc control settings. This kind of setting regulation is referred to as controller
tuning [19]. Diﬀerent PID controller tuning techniques exist, and they all aim to22 2. CONTROL ALGORITHMS AND MODELS
Figure 2.3: PID control contribution during an hyperglycemic clamp [21].
provide a good initial setting that can be later improved on-line. A method widely
used for the PID controller design for the artiﬁcial pancreas system is Internal
Model Control.
Since it is a model-based method, this technique provides the best performance
when a reasonable accurate dynamic model is available [19].
2.1.4 Controller Tuning Using The IMC method
The basic idea of the IMC method is the controller should include a model of
the controlled process. Ideally, if the process model is perfect and there are no
disturbances identiﬁed, the control will be perfect. The structures of both IMC
and the classical feedback control are shown in Figure 2.4 and Figure 2.5. The two
structures are related by an algebraic transformation. Once IMC controller G∗
c is
designed it can be implemented as the corresponding classical PID controller Gc
[19]:
Gc =
G∗
c
1 − ˜ Y G∗
c
(2.13)
G
∗
c =
Gc
1 + ˜ Y Gc
(2.14)
The relation of input to output for the IMC block diagram is:
Y =
G∗
cG
1 + G∗
c(G − ˜ G)
YsP +
1 − G∗
c ˜ G
1 + G∗
c(G − ˜ G)
D (2.15)2.1. CONTROL ALGORITHMS 23
where D is an external disturbance.
Figure 2.4: Internal Model Control blocks diagram scheme [19].
Figure 2.5: Classical feedback blocks diagram scheme [19].
This G∗
ccontroller is designed in two main steps [22]:
1. Obtain a simple transfer function model (e.g, ﬁrst/second order model plus
time delay) from the original process model (model approximation)
2. Calculate PID settings from simple model (PID Tuning).
Step 1: Model Approximation
This step consists of approximate an original transfer function model G0(s) form
which can be approximated either theoretically or empirically [22].
FOPTD model:
˜ G(s) =
K
(τs + 1)
e
−s (2.16)
SOPTD model:
˜ G(s) =
K
(τ1s + 1)(τ2s + 1)
e
−s (2.17)24 2. CONTROL ALGORITHMS AND MODELS
Consequently, the approximate model is determined by following model parame-
ters:
a) model gain K
b) lag time constant (τ or τ1 andτ2)
c) time delay θ
In order to compute the model parameters from the higher order model, Skoges-
tad’s Half Rule [22] can be applied.
Skogestad's Half Rule (JPC 2002)
The model approximation of the model is mainly based on two Taylor approxi-
mations of the time delay transfer function:
e
−s ≈ 1 − θs (2.18)
or
e
−s =
1
es ≈
1
1 + θs
(2.19)
Using the ﬁrst the ﬁrst approximation in (2.18), a negative numerator term
(a right half plane zero) can be approximated as a time delay:
(−T0s + 1) ≈ e
−T0s (2.20)
where T0 > 0, in the same way, a small time constant τ0 can be approximated as
a time delay using Eq. (2.19):
1
τ0s + 1
≈ e
−0s (2.21)
Consequently, considering either approximation Eq. (2.20) and approximation
Eq. (2.21), the eﬀect delay is the sum of the original delay and the approximated
terms as demonstrated in [22]:
−T0s + 1
τ0s + 1
e
−0s ≈ e
−0se
−T0se
−0s = e
−(0+T0+0)s = e
−s (2.22)
Consider an original model in the form:
˜ G(s) =
∏
j(−Tj0 + 1)
∏
i(τi0 + 1)
e
−0s (2.23)2.1. CONTROL ALGORITHMS 25
lags τi0 are in descending order and Tj0 > 0.
The two approximated models are:
FOPTD model:
τ1 = τ10 +
τ20
2
(2.24)
θ =
τ20
2
+ τ20 + θ0 + 3T0 +
Ts
2
(2.25)
SOPTD model:
τ1 = τ10 (2.26)
τ2 = τ20 +
τ20
2
(2.27)
θ =
τ20
2
+ θ0 + 3T0 +
Ts
2
(2.28)
where Ts is the sampling time for the digital implementation of a PID controller
[22].
Step 2: PID tuning
In the IMC design PID tuning is a two step procedure.
1. The process model obtained with the half rule is factored as:
˜ G(s) = ˜ G+(s) ˜ G−(s) (2.29)
where ˜ G+(s) contains time delays and any right-half plane zeros, and there-
fore it is the non-invertible component. In contrast, ˜ G−(s) is the invertible
term.
FOPTD model In this case the time delay term is approximated with a
Pad´ e approximation :
e
−s =
1 − 
2s
1 + 
2s
(2.30)26 2. CONTROL ALGORITHMS AND MODELS
Therefore, the factorization of the process model becomes:
˜ G+(s) = 1 −
θ
2
s (2.31)
˜ G−(s) =
K
(τs + 1)(
2s + 1)
(2.32)
SOPTD model Factorization of the process model with the Taylor series
approximation:
˜ G+(s) = 1 − θs (2.33)
˜ G−(s) =
K
(τ1s + 1)(τ2s + 1)
(2.34)
2. In this step, the IMC controller includes a ﬁlter f with a steady-state gain
of one with the common form:
G
∗
c =
1
˜ G−(s)
ff =
1
(τcs + 1)
(2.35)
τc is an adjustable parameter which determines the speed-of-response. In
particular, if it increases, the speed of response decreases and vice versa.
In order to compensate the mismatch between the process model and the
actual process, τc can be adjusted and a higher value of τc will determine a
robust control system [19]. The ﬁnal IMC controller will be:
G
∗
c =
1
˜ G−(s)
1
(τcs + 1)
(2.36)
Once the IMC controller with the two steps is designed, it can be easily brought
back to a PID controller with the relationship in (2.13):
Leading to the PID tuning for FOPTD model [19]:
Kc =
1
K
τ + 
2
τc + 
2
(2.37)
τI = τ +
θ
2
(2.38)
τD =
τθ
2τ + θ
(2.39)
For the SOPTD model
Kc =
τ1 + τ2
K(τc + θ)
(2.40)
τI = τ1 + τ2 (2.41)
τD =
τ1τ2
τ1 + τ2
(2.42)2.2. PROCESS MODELS 27
2.2 Process Models
In light of the relevant role that models play for a glucose controller development,
it is quite understandable that the lack of accurate models for individual sub-
jects is a key problem in the development of reliable closed-loop control system.
A patient-model mismatch could cause hypoglycemia and the controller perfor-
mance would be reduced. In particular, it can be argued that the needs which
a model should satisfy may change in the diﬀerent phases, e.g; design, tune and
validation. Indeed, models for the controller design are generally compact in or-
der to capture the system dynamic behaviors. On the other hand, the controller
tuning and validation stages should make use of more detailed simulations which
mimic the real system dynamics in a faithful way [20].
Over the years, diﬀerent types of models which describe the insulin/glucose
dynamic ( also called ”glucose kinetics models”[16] ) have been proposed and an
exhaustive overview can be found in the literature citeBequette2005, Steil2005,
Cobelli2009.
Some models consist of ordinary or partial diﬀerential equations, artiﬁcial
neural networks (ANNs), fuzzy logic or expert systems. In the physiological envi-
ronment, compartmental models are often employed and they are based on ordi-
nary diﬀerential equations. The most widely used model is the so-called ”minimal
model”of Bergman et al. Figure 2.6 [23]. The aim of this model is to provide a
description of the insulin/glucose dynamic in as simple a way as possible, i.e with
a minimum number of known or assumed parameters [11, 16, 24].
The model is described by the following diﬀerential equations:
dG(t)
dt
= (p1 − X(t))G(t) − p1Gb (2.43)
dX(t)
dt
= p2X(t) + p3I(t) (2.44)
dI(t)/dt = E(t) − n(I(t)) (2.45)
The dependent variables are G(t), I(t) and X(t) indicate the plasma glucose the
plasma insulin and the insulin concentration in a remote compartment, respec-28 2. CONTROL ALGORITHMS AND MODELS
tively. Insulin is assumed to be delivered only through exogenous means E(t) and
the parameters pi and n are characterized by the individual patient. Gb is the
basal glucose concentration. In recent studies, it was found that this model over-
estimates the ability of glucose to facilitate its own uptake and underestimates the
contribution of elevated insulin levels [24]. Moreover, in this model, a description
of how the system behaves after a meal disturbance, and of the insulin kinetics
response to a subcutaneous insulin delivery, is not included. Other examples of
well-known models are the AIDA model and Sorensen’s model [16].
Alternatively, empirical models can be obtained from data. An eﬀort to iden-
tify models retrieved from patient data can be found in [25] where various diﬀerent
data-based modeling approaches to diabetes mellitus are analyzed. On the basis
of a patient’s daily glucose monitoring, data-base models were developed. The
glucose-insulin system was simpliﬁed and reduced at three main parts because of
the modeling goal: the Glucose Sub-Model(GSM), the Insulin-Sub-Model (ISM)
and the Glucose-Insulin-Interaction-Model (GIIM). The three parts are modeled
separately using mainly compartment models and black-box models. In partic-
ular, the GSM describes the glucose absorption from meal, the ISM describes
the absorption of insulin from insulin injection and the GIIM the interaction of
glucose and insulin in the blood systems and organs. The results of this model-
ing approach based on the patient data show that they are often inaccurate for
several reasons. One relevant cause of the accuracy problems is that clinical data
in T1DM locks suﬃcient excitation for model identiﬁcation.
Autoregressive models (AR) have also been investigated for the blood glucose
value prediction in order to address the identiﬁability issues, but they are not
suitable for control applications because they do not contain an exogenous input
[1]. In order to overcome the exogenous input limit, the autoregressive exogenous
input (ARX) model have been demonstrated as a valid choice for control [4].
Fuzzy logic is also applied to the model identiﬁcation aim. In a process in which
a particular change in the input variable may result in three diﬀerent magnitudes
of changes in the output, the fuzzy logic provides a way to indicate that the
output might be a mix of two of the magnitudes, for example. Expert systems
are based on the knowledge of an ”expert” that has a good understanding of the2.2. PROCESS MODELS 29
system. For examples, this kind of model can be used as protocols for insulin
delivery in critical care. In this case, clinicians would introduce speciﬁc rules such
as the required units of insulin for a given blood glucose amount. This kind of
approach can also be implemented in a fuzzy logic-based framework [11].
The ANNs models derived by physiological description of the function of neu-
rons and neural networks in animals. An ANN model is normally used to provide
a nonlinear relationship between inputs and outputs. The procedure consists of
two steps: training and veriﬁcation. In the ﬁrst step, an ANN model is trained
with a known input and output data, and it ﬁnds the best data ﬁt with an opti-
mization of the ANN parameters. Then, a veriﬁcation with diﬀerent input-output
data from the one used for the training is conducted [11].
2.2.1 Control-relevant Models
All the models listed above are suitable both for a control purpose and for the
prediction of the patient behavior. However, some of them are more appropriate
for prediction rather than a control purpose. An important class of models for
control system design is called control-relevant models. The main idea behind
this type of model is that they are developed for the speciﬁc control goal rather
than for the optimization of the prediction of future glucose value [1].
In order to achieve an accurate prediction of the patient’s behavior, detailed
models are more suitable, containing large number of parameters and diﬀerential
equations along with nonlinearities which are typical for biological process [24].
However, when the purpose is diﬀerent from prediction, the control-relevance
issues must be addressed. An example of a model with a high level of complexity
can be the detailed compartment model of glucose-insulin interaction [26], which
contains 19 total diﬀerential equations, Figure 2.7, rather than the 3 diﬀerential
equations in the Bergman ’Minimal Model’.
As mentioned above, the performance of a model-based control, e.g IMC-
PID, is directly related to the model accuracy. In spite of the need for reﬁned and
accurate models, a good control performance can be achieved with approximate
models whose requirements for control are based on frequency-domain arguments.
Hence, an approximate model needs to be accurate at frequencies around the30 2. CONTROL ALGORITHMS AND MODELS
closed-loop bandwidth in order to achieve a robust control performance which is a
prerequisite in the artiﬁcial pancreas design. Indeed, if the correct frequency range
is captured, a large amount of mismatch in an open-loop simulations response can
be tolerated without leading to a decrease in the closed loop performance [1].
Figure 2.6: Schematic overview of the ’Minimal Model’ of Bergman et al. [24].
Figure 2.7: Detailed scheme for the insulin-glucose interactions [24].
Another key issue in ﬁnding proper models for control is the necessity of a
personalization of the control algorithm. The artiﬁcial pancreas should ideally2.2. PROCESS MODELS 31
perform safely and satisfactorily for all the patients. Unfortunately, the intra-
individual and the inter-individual variability among the subjects make it diﬃcult
to achieve the controller robustness and if model and/or controller personalization
is not implemented. On the other hand, identiﬁcation of accurate individual mod-
els is very diﬃcult. A solution to this problem has been proposed by van Hausden
et al. [1], where parametric models are ﬁrst identiﬁed to provide a model structure
that captures the the dynamic around the expected closed-loop bandwidth. Then,
a ﬁxed model is deﬁned which underestimates the robustness margins. Finally,
a personalization of the model is achieved by modifying the model gain of the
model for each subject on the basis of the a priori patient characteristics such as
the total daily insulin (TDI).
2.2.2 Novel PID Control Approach Based on Personalized
Model
The PID control algorithm for automated closed-loop insulin delivery system has
been widely applied. In [16] PID control algorithm was used in order to demon-
strate the feasibility of a closed-loop insulin delivery system based on subcuta-
neous insulin delivery and subcutaneous glucose sensing. In [18] the PID algo-
rithm was used to evaluate the eﬀect of controller gain on the insulin response
to a meal. In both cases the controller gain was calculated taking into account
the subject’s TDI value. In [17] a combination of insulin boluses and PID control
with switching criteria has been evaluated.
The novel approach proposed in this thesis consists in the use of a control-
relevant model in order to design the PID controller, reducing the three tuning
terms (proportional, derivative and integral terms) to two tuning variables that
aﬀect the controller gain: the model gain (K) and the speed of response to the
meal (τc) as showed in Eq. (2.40). Furthermore, the model gain, and consequently
the controller gain, are personalized based on the subjects’ TDI value.
The detailed of the model, personalization of the gain and controller imple-
mentation will be presented in the next chapterChapter 3
Controller design and
Implementation
In this chapter the details of the controller design and its implementation are pre-
sented. In particular, the main design issues are analyzed, and a brief description
of the process model identiﬁcation is provide, as well. Then, each implementation
step is reported.
3.1 Main Design Issues
Even though the APS is supposed to improve glycemia control and thus avoiding
high glucose blood values, it is important to emphasize the risks it may introduce.
The main risk is hypoglycemia that occurs when the blood glucose concentration
is below 60 mg/dl. This undesirable situation usually occurs after a meal intake,
when the corresponding insulin bolus is too large. The increasing concentration
of blood glucose after a meal may cause an over-delivery by the controller which
will not be detected immediately, anditis too late to turn oﬀ the insulin delivery
[1]. For this reason, avoiding postprandial hypoglycemia turned to be the most
diﬃcult challenge in developing an artiﬁcial pancreas controller. The main cause
of a controller failure in regulating blood glucose and avoid hypoglycemia events
is the inter-subject and intra-subject variability, leading to a patient-model mis-
match. As a results of this mismatch, the controller can be either too aggressive34 3. CONTROLLER DESIGN AND IMPLEMENTATION
or too conservative. With a conservative controller, the meal response will be too
slow to overcome hyperglycemia, on the other hand, an aggressive controller will
provide more insulin than is desired, leading to low glycemic blood values.
The model identiﬁcation is the ﬁrst step in designing a robust controller al-
gorithm which minimize the risk of hypoglycemia. Then, the tuning parameters
can be optimized by using a personalized model, and thus a personalized control
algorithm.
3.2 Model Identication
The aim of this research is to use simple control-relevant models in order to
develop a PID-IMC controller for the Artiﬁcial Pancreas System, designing in-
cluding the process model dynamics. Over the years, many models have been
developed and used in order to design diﬀerent controllers as decribed in Chapter
2. However, the main characteristic of this new type of control-relevant model
is that it is more focused on achieving the desired control performance rather
than providing an optimum prediction of the glucose blood concentration. Since
the main aim in developing a controller for the artiﬁcial pancreas system should
always be the safety of the patient, a valid control algorithm should either pre-
vent risk situations of hypoglycemia and at the same time meet the performance
speciﬁcations.
The personalized control-relevant models proposed by Van Heusen et al. [1]
introduce a priori information in the model in order to guarantee robustness
in case the patient’ s dynamics signiﬁcantly diﬀer from the model. The model
identiﬁcation in [1] is conducted in silico with 10 representative subjects of the
UVA/Padova metabolic simulator with a protocol that cannot be performed in a
clinical environment, but with all the important information and without noise
information required. In the experiment, the total simulations lasts 72 hours, and
three bolus of 1, 2 and 3 units, respectively, is provided to the 10 subjects. The
ﬁrst bolus is given after the subjects reach the fasting blood glucose. The second
bolus is delivered after 24 hours and the third bolus after 48 hours. For each
subject a transfer function is estimated. The cross-over frequency of the open-loop3.2. MODEL IDENTIFICATION 35
systems, frequency at which the phase angle curve crosses zero degrees, is found
to be approximately 2 × 10−4 rad/s and, therefore, the closed loop bandwidth
is expected to be between 5 × 10−5 rad/s and 4 × 10−4 rad/s [1]. The model
input is the insulin delivered by the pump and the output is the blood glucose
concentration. In Van Heusen et all. a discrete third-order transfer funtion model
is deﬁned:
Mr(z
−1) =
G(s)
I(s)
=
Kz−3
(1 − 0.98z−1)(1 − 0.965z−1)2 (3.1)
where
K = −2.005 × 10
−4 (mg/dl)/(pmol/min)
The insulin units are (pmol/min) and the glucose units are (mg/dl). The Bode
diagram of this model is compared to the ten subjects’ Bode diagrams in Fig-
ure 3.1. The phase for the model is lower and its gain is overestimated, leading
to a more robust and conservative control if the expected closed-loop bandwidth
is correct.
Personalized Models
A conservative model ﬁxed gain that may result in poor controller performance
when a sugniﬁcant patient-model mismatch occurs. This problem can be min-
imyzed by replacing the ﬁxed model gain with a gain that is personalized for
each subject using a priori information. The dynamics of the personalized model
are ﬁxed, but, the gain is adjusted on the basis of subject’s sensitivity to insulin.
The model with the personalized gain is in the form:
Mi(z
−1) =
G(s)
I(s)
=
FsKicz−3
(1 − 0.98z−1)(1 − 0.965z−1)2 (3.2)
Where Mi is the model for subject i, Fs is the safety factor, Ki is the individualized
gain which is calculated based on the subject’s total daily insulin (TDI) with the
2400 rule:
Ki =
2400
TDI
(3.3)36 3. CONTROLLER DESIGN AND IMPLEMENTATION
Figure 3.1: Bode diagrams for the model (blue line) and for the ten subjects (gray
lines) [1].
and c is a constant determined in part by the units used and in part by a
scaling factor. In ths research, c = 1.255 × 10−6 (pmol/min/U/h). The safety
factor Fs is chosen by the physician. Its value is normally ≤ 1 and guidelines
which suggest how to select the safety factor are available in [1]. The aim of the
safety factor is to compensate the uncertainty due to the underestimation of the
TDI. In this thesis Fs is considered to be equal to 1. The design of any linear
model-based controller can be conducted using this personalized model [1].
3.3 Controller Design
The controller design consists of two main steps: (i) ﬁnd a continuous low-order
approximation of the transfer function model in Eq. (3.2) and (ii) use this ap-
proximation to implement a PID controller using the IMC design method. In the
following two sections, these two steps are described.3.3. CONTROLLER DESIGN 37
3.3.1 Model Approximation
In order to design an IMC controller, the ﬁrst step is to ﬁnd the continuous
control-relevant model starting from its discrete form.
The bilinear (Tustin) transform approximation is a simple and easy to use
method in order to relate the s- and z- domains. It is in the form:
z = e
sTs ≈
1 + sTs/2
1 − sTs/2
(3.4)
where Ts is the sampling period of the discrete system (Ts = 5 min) [27].
After, applying the approximation to the discrete model, the following continuous
transfer function model is obtained in the gain time-constant form (in h):
Mr(s) =
K(−0.03s + 1)3e−0:25s
(4.12s + 1)(2.33s + 1)2 (3.5)
K = −8.184 (mg/dl)/(pmol/min)
Its Bode digram is shown in Figure 3.2
The expected frequency of interest is between 5×10−5 rad/s and 4×10−4 rad/s.
Since any model which shows the current dynamic behavior for this frequency
range would be satisfactory for the controller design, the Mr continuous transfer
function is a good approximation.
Next, the model in Eq. (3.6) is reduced to either a second and ﬁrst-order model
plus time-delay (FOPTD or SOPTD) using Skogestad’s Half Rule in Chapter 2.
Mr(s) =
Ke−0s(−T0s + 1)3
(τ10s + 1)(τ20s + 1)2 (3.6)
K = −8.134 (mg/dl)/(pmol/min)
T0 = −0.03 h
τ10 = 4.12 h
τ20 = 2.33 h
θ = 0.25 h38 3. CONTROLLER DESIGN AND IMPLEMENTATION
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Figure 3.2: Bode diagram of Mr continuous transfer function3.3. CONTROLLER DESIGN 39
Applying Eq. (2.24) and Eq. (2.25) gives:
τ1 = τ10 +
τ20
2
= 5.3 h (3.7)
θ =
τ20
2
+ τ20 + θ0 + 3T0 +
h
2
= 3.9 h (3.8)
Obtaining the FOPTD model:
M
′
r(s) =
Ke−3:9s
5.3s + 1
(3.9)
And applying Eq. (2.26)-2.28 gives:
τ1 = τ10 = 4.12 h (3.10)
τ2 = τ20 +
τ20
2
= 3.49 h (3.11)
θ =
τ20
2
+ θ0 + 3T0 +
h
2
= 1.56 h (3.12)
And the SOPTD model:
Mr(s)
′′ =
Ke−1:56s
(4.12s + 1)(3.49s + 1)
(3.13)
K = −8.184 (mg/dl)/(pmol/min)
From Figures 3.3 and 3.4 a comparison between the discrete model presented
by Van Husen et al. [1] and its continuous approximation as either a FOPTD
or SOPTD is provided. In Figure 3.3 the Bode diagrams show that the approx-
imations are similar to the discrete model in the frequency range of interest. In
Figure 3.4 the step responses of the three models are very similar. Nevertheless,
considering both the Bode diagrams and the step responses, the SOPTD model
provides the bettere approximation. For this reason the model chosen for the
IMC-PID controller desogn was the SOPTD model.40 3. CONTROLLER DESIGN AND IMPLEMENTATION
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3.3.2 PID Controller Tuning
In a SOPTD model, Eqs. 2.40 to 2.42 lead to the following PID controller settings:
Kc =
7.61
K(τc + 1.56)
(3.14)
τI = 7.61 h (3.15)
τD = 1.89 h (3.16)
3.4 Simulator PID Implementation
The two main parts of the controller part of the simulator are a setup script
and a run-time algorithm. The setup script allows the controller to be tuned
for each subject and thus provides the personalized information to the run-time
controller. The run-time algorithm applies the tuned control algorithm. The con-
trol algorithm is implemented in the form of a Simulink R ⃝ block and the input
and output of the control block are ﬁxed. In the main panel of the Simulink R ⃝
simulator, Figure 3.5 the control law block is the orange block at the bottom.
Within the orange block the controller was implemented. For the ﬁrst imple-
mentation of the controller, the noise introduced by the CGM sensor was not
considered, and glucose concentration values are provided to the PID controller
from the input 1 (glucose). In the PID block the PID algorithm was implemented.
3.4.1 Discrete PID Control
Since the CGM device provides samples of the subcutaneous glucose amount every
ﬁve minutes, the digital implementation of the parallel form of the PID controller
was considered. The discrete IMC-PID algorithm was implemented with an m-
ﬁle in the controller block. In order to obtain the discrete form, the integral and
derivative terms in Eq. (2.10) were replaced by diﬀerence approximations.42 3. CONTROLLER DESIGN AND IMPLEMENTATION
∫ t
0
e(t
∗)dt
∗ ≈
k ∑
j=1
ej∆t (3.17)
de
dt
≈
ek − ek−1
∆t
(3.18)
∆t : Ts
ek : error at the kth sampling instant fork=1,2..
With this two approximation, the discrete PID control algorithm becomes:
uk = ¯ u + Kc
[
ek +
∆t
τI
k ∑
j=1
ej +
τD
∆t
(ek − ek−1)
]
(3.19)
uk : is the controller output at the kth sampling instant.
In order to avoid the derivative kick issue, the derivative action is applied only
at the measured subcutaneous glucose concentration rather than the error signal
as well as in the continuous manner. The resulting digital PID formula will be:
uk = ¯ u + Kc
[
ek +
∆t
τI
k ∑
j=1
ej +
τD
∆t
(ym;k−1 − ym;k)
]
(3.20)3.4. SIMULATOR PID IMPLEMENTATION 43
Figure 3.5: The UVA/Padova metabolic simulator. Main panel with the control
law block at the bottom(orange).Chapter 4
Controller With a
Non-personalized Controller Gain
In this chapter, ﬁrst a population of ten representative subjects from the UVA/Padova
metabolic simulator is used to investigate the best tuning of the PID controller
for a single non-personalized model. Then, a diﬀerent population of ten subjects
is used to validate the selected controller tuning. The main results for all the sim-
ulations conducted are reported in this chapter, and in Appendix all the single
subject results are reported as well.
4.1 Eect of τc
In this section the results of controller tuning are reported. Since the controller
gain is not personalized and thus is ﬁxed for each subject, the only tuning pa-
rameter is τc. A population of ten adult subjects of the UVA/Padova metabolic
simulator is used to conduct simulations in order to evaluate the eﬀect of τc on
the controller performance for post-prandial conditions. The scenario chosen for
the on-line tuning is:
• t=2 h: controller turned on;
• t=7 h: a single meal of 50 g CHO is given to the subject;
• t=30 h: simulation ends.46 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
The controller set point is 110 mg/dl for all the subjects. The simulation lasts 30
h in order to observe the entire response and determine whether or not the set
point is reached for the critical case of undershoot and hypoglycemia. Based on
the FOPTD model in Eq. (3.9), three values of τc were considered: τc=1, 2 and 5
h.
Table 4.1 shows the PID controller settings for these three values of τc. Note
that controller aggressiveness decreases as τc increases because Kc also decreases
(in absolute values).
Table 4.1: PID settings for diﬀerent values of τc
τc Kc τI τD
h pmol/minmg/dl h h
1 -0.37 7.63 1.88
2 -0.26 7.63 1.88
5 -0.14 7.63 1.88
The simulation results for the three diﬀerent values of τc are reported in
Figures 4.1- 4.3 and Tables 4.2 and 4.3. Observing the glucose concentration (at
the top of each ﬁgure) as well as the insulin infusion rate (at the bottom), the eﬀect
of τc on controller of aggressiveness is quite evident. No hypo- or hyperglycemia
events occurred. Furthermore, the blood glucose concentration is never below 80
mg/dl for all the subjects and τc values. For τc = 1 h, all the subjects except ♯ 6
reach the set point. Moreover, there were only three subjects (♯ 4, 6 and 7) that
show undershoot; however, their minimum glucose values were well above the
hypoglycemia threshold of 80 mg/dl. Results for τc = 1 h do not diﬀer so much
from the τc = 2 h case. Responses for τc = 5 h reveal a less aggressive controller
output, since none of the subjects shows glucose values below 99 mg/dl and most
of them do not reach the set point during the simulation time, the lowest glucose
value mean is 116 ± 10 mg/dl.
The idea that a more conservative response lead to higher glucose peak is
conﬁrmed by comparing the ∆G values in Table 4.3, where the mean of the
glucose peak relative to the value at tmeal is 69 ± 22 for τc = 1 h and 83 ± 24 for4.1. EFFECT OF τC 47
τc = 5 h. The glucose concentration remains within the glucose range 80÷ 140
(normo-glycemia range) for 66(±13)% of the time for τc = 1 h, whereas in τc =
5 h glucose concentration remains only 55(±15)% of the time in the same range.
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Figure 4.1: Post-prandial responses for τc = 1 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).48 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
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Figure 4.2: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glicemia
zone (80-140 mg/dl).
0 5 10 15 20 25 30
60
80
110
140
160
190
220
250
Time [h]
G
l
u
c
o
s
e
 
[
m
g
/
d
l
]
 
 
sub1
2
3
4
5
6
7
8
9
10
0 5 10 15 20 25 30
0
0.5
1
1.5
2
2.5
Time [h]
I
n
s
u
l
i
n
 
[
U
/
h
]
 
 
sub1
2
3
4
5
6
7
8
9
10
Figure 4.3: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glicemia
zone (80-140 mg/dl).4.1. EFFECT OF τC 49
Table 4.2: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects.
range τc = 1 h τc = 2 h τc = 5 h
60<G<80 0 0 0
80<G<140 66 (± 13) 63 (±13) 55 (±15)
70<G<180 88 (±6) 86 (±6) 84 (±5)
180<G<250 12 (±6) 14 (±6) 16 (±5)
Table 4.3: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax−Gmeal. Gmax is the maximum blood glucose value and Gmin is the minimum
value, during the post-prandial response. tr is the time to return to the normo-
glycemia zone after the meal.
metrics τc = 1 h τc = 2 h τc = 5 h
∆G (mg/dl) 69 (±22) 75 (±22) 83 (±24)
Gmax (mg/dl) 212 (± 21) 218 (±22) 225 (±23)
Gmin (mg/dl) 104 (±9) 108 (±9) 116 (±10)
tr (h) 6.5 (±2) 7 (±2) 9 (±2)
In Figures 4.4 and 4.5 the eﬀect of the three diﬀerent τc values for subject ♯ 5
and 6 is showed. Subject ♯ 6 shows the most undershoot among all the subject,
and when τc = 1 h the controller performance in term of time required to make
the glucose return in the normo-glycemia zone is improved (7.1 h, Table C.5)
compared to τc = 5 h (10.6 h, Table C.5), subject ♯ 6 shows a longer undershoot for
τc = 1 h, but still remains in the normo-glycemia range (88 mg/dl is the minimum
glucose value). For ♯ 5 the diﬀerence in the glucose concentration between the
eﬀect of the τc is not so marked. However, a better performance for τc = 1 can
be observed.50 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
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Figure 4.4: Post-prandial responses for subject ♯ 5 and diﬀerent τc value. The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glicemia zone (80-140 mg/dl).
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Figure 4.5: Post-prandial responses for subject ♯ 6 and diﬀerent τc value. The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glicemia zone (80-140 mg/dl).4.1. EFFECT OF τC 51
4.1.1 Robustness Test
Although these results show a better performance for τc = 1 h for all the subjects,
another test should be conducted in order to verify the controller robustness, be-
fore establishing the best PID controller tuning settings. The objective of the
robustness test was to verify the controller behavior for intra-subject insulin sen-
sitivity changes of ±50%. Thus, the controller output was reduced and increased
by 50%, to mimic the decrease and increase of the insulin sensitivity for the
same scenario. The robustness test results with the controller output ±50% are
reported for each τc value.
τc = 1 h
Robustness results for τc = 1 h are reported in Figus. 4.6-4.9.When the controller
output is reduced by 50%, the glucose concentration is in general higher compared
to the the one obtained with the normal controller output, for all the subjects. On
the other hand, the undershoot smaller; however, after the meal, all the subjects
return around the set point value at the end of the simulation.
With the controller output is increased by 50%, the controller aggressiveness
results in lower the glucose concentration peaks and in a pronounced undershoot,
but never below the the normo-glycemia lower bound (80 mg/dl).
Subject ♯ 6, as observed also in the previous results, show the most critical
case, therefore the three output conditions for this subject are reported. However,
for all the three conditions (normal, output controller ±50%) the controller per-
forms well, avoiding hypo- hyperglycemia events, even with the subject is more
sensitive to the insulin.52 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
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Figure 4.6: Post-prandial responses for τc = 1 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.
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Figure 4.7: Post-prandial responses for τc = 1 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.4.1. EFFECT OF τC 53
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Figure 4.8: Post-prandial responses for subject ♯ 5, τc = 1 h and the three controller
output conditions (normal, increase by 50% and decrease of the 50%). The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glyciemia zone (80-140 mg/dl).
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Figure 4.9: Post-prandial responses for subject ♯ 6, τc = 1 h and the three controller
output conditions (normal, increase by 50% and decrease of the 50%). The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glyciemia zone (80-140 mg/dl).54 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
τc = 2 h
Robustness results for τc = 2 h are reported in Figures 4.10-4.13 and they similar
to the robustness results for τc=1 h. Nevertheless, when the controller output is
decreased, the controller action results to be less aggressive and some subjects
are not longer close to the set point at the end of the simulation.
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Figure 4.10: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.
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Figure 4.11: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is increased by 50%4.1. EFFECT OF τC 55
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Figure 4.12: Post-prandial responses for subject ♯ 5, τc = 2 h and the three con-
troller output conditions(normal, increase by 50% and decrease of the 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).
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Figure 4.13: Post-prandial responses for subject ♯ 6, τc = 2 h and the three con-
troller output conditions(normal, increase by 50% and decrease of the 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).56 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
τc = 5 h
Robustness results for τc=5 h are reported in Figures 4.15-4.17. When the con-
troller output is reduced by 50%, the controller is less aggressive and is not able
to bring the glucose concentration close to the set point for the majority of the
subjects, even thought there are no cases of undershoot. The insulin delivered
by the pump at the bottom of the Figure 4.15 show that the controller is not
aggressive enough, since when the meal is detected (blue bar for t = 7 h), a really
small response is performed by the controller.
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Figure 4.14: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.4.1. EFFECT OF τC 57
0 5 10 15 20 25 30
60
80
110
140
160
190
220
250
Time [h]
G
l
u
c
o
s
e
 
[
m
g
/
d
l
]
 
 
sub1
2
3
4
5
6
7
8
9
10
0 5 10 15 20 25 30
0
0.5
1
1.5
2
2.5
3
3.5
Time [h]
I
n
s
u
l
i
n
 
[
U
/
h
]
 
 
sub1
2
3
4
5
6
7
8
9
10
Figure 4.15: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is increased by 50%.
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Figure 4.16: Post-prandial responses for subject ♯ 5, τc = 5 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).58 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
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Figure 4.17: Post-prandial responses for subject ♯ 6, τc = 5 h and the three con-
troller output conditions(normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).
In Tables 4.4-4.7 the robustness results for diﬀerent τc values are reported
in terms of means and standard deviations. There are no cases of hypoglycemia
or hyperglycemia, and none of the subjects shows glucose concentration in the
range 60-80 mg/dl. According to the ﬁgures and tables, τc = 1 h shows the best
performance. Indeed, when the controller output is increased by 50%, the glucose
concentration remains in the range of normo-glycemia 80-140 for 73 (±12)% of
the time, whereas for τc = 5 h only for 63(±13)% of the time . Percentage of time
spent in the range 180-250 changes from 8% (±5%) to 13% (±6%) with τc = 1 h
and 5 h, respectively. When the controller output is decreased by 50%, the time
spent in the range 80-140 is 62(±14)% for τc = 1 h and 51(±15)%.4.1. EFFECT OF τC 59
Table 4.4: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects,
when the controller output is increased by 50%.
range τc=1 h τc=2 h τc=5 h
60<G<80 0 0 0
80<G<140 73 (± 12) 69 (±12) 63 (±13)
70<G<180 92 (±5) 89 (±5) 87 (±6)
180<G<250 8 (±5) 11 (±6) 13 (±6)
Table 4.5: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects,
when the controller output is decreased by 50%.
range τc = 1 h τc = 2 h τc = 5 h
60<G<80 0 0 0
80<G<140 62 (± 14) 58 (±14) 51 (±15)
70<G<180 86 (±6) 85 (±5) 82 (±5)
180<G<250 14 (±6) 16 (±5) 17 (±4)60 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
Table 4.6: Single meal statistics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax − Gmeal. Gmax is the maximum glucose concentration value. Gmin is the
minimum value. tr is the time to return to the normo-glycemia zone after the
meal. the controller output is increased by 50%.
metrics τc = 1 h τc = 2 h τc = 5 h
∆G (mg/dl) 57 (±20) 63 (±21) 73 (±22)
Gmax (mg/dl) 199 (± 19) 205 (±20) 216 (±22)
Gmin (mg/dl) 95 (±8) 100 (±8) 122 (±10)
tr (h) 5 (±2) 6 (±2) 7 (±2)
Table 4.7: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax − Gmeal. Gmax is the maximum blood glucose value. Gmin is the minimum.
tr is the time to return to the normo-glycemia zone after the meal. the controller
output is decreased by 50%
metrics τc = 1 h τc = 2 h τc = 5 h
∆G (mg/dl) 76 (±23) 80 (±23) 86 (±25)
Gmax (mg/dl) 218 (± 22) 223 (±23) 228 (±24)
Gmin (mg/dl) 110 (±9) 114 (±10) 122 (±10)
tr (h) 7 (±2) 8 (±2) 10 (±3)4.2. VALIDATION TEST: POST-PRANDIAL RESULTS 61
4.1.2 Discussion
Both the results for the eﬀect of the τc values and the robustness test show that the
best PID tuning results are for τc = 1 h. The mean values is of 6.5 h to return in
the normo-glycemia zone after the meal intake, the highest glucose concentration
value is 247 mg/dl for subject ♯ 10 when controller output decreased by 50%, and
the lowest glucose concentration value is 86 mg/dl when the controller output is
increased by 50%. These results ensure that for this value of τc a safe controller
results, avoiding any dangerous cases of hypo- or hyperglycemia.
4.2 Validation Test: Post-prandial Results
Once the eﬀect of τc values has been analyzed and has been observed that the best
controller performance is achieved for τc = 1 h, a validation test is conducted. A
population of new 10 subjects (diﬀerent from the previous 10 subjects population)
from the UVA/Padova metabolic simulator is used to investigate the controller
performance when three meals (dinner, breakfast and lunch) are provided. The
validation test scenario is:
• t=0 h (1 pm): simulation starts
• t=2 h (3 pm): controller turned on;
• t=5 h (8 pm): a meal of 50 g CHO (dinner) is given;
• t=16 h (7 am): meal of 40 g CHO (breakfast) is given;
• t=21 h (12 pm): meal of 50 g CHO (lunch) is given t;
• t=30 h (9 pm): simulation ends.
Figure 4.18 and Tables 4.8-4.11 show the validation test results. The ﬁrst
important result is that none of the subjects had hypoglycemic events. More-
over, only 1.6% (±2.7%) of the time the glucose concentration remains within
the range 60-80 in average (values of 7,3, and 6 % for subjects ♯ 6, 9, and 10
respectively). The minimum glucose value is 70 mg/dl for subject ♯ 6 and, from62 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
Figure 4.18, it occurs around 9 pm, when another meal is given. In particular,
the controller action for subject ♯ 3 and 9 is good, since they remain in the range
70-180 for all the simulation. Only subjects ♯ 1, 6, and 10 show hyperglycemia
events; nevertheless the highest glucose values are moderate: 279, 182 and 252
mg/dl respectively. The time to return in the normo-glycemia zone after meal is
less than 7.3 h after the ﬁrst meal; after the second meal some of the subjects
do not even reach the normo-glycemia zone (♯ 5, 7 and 8) before the third meal
is provided. After the third meal, the time to reach the normo-glycemia zone is
less 6.5 h for all ten subjects. Subjects ♯ 9 and 3 after the ﬁrst meal return in the
normo-glycemia zone for almost all the time.
These results demonstrate that the choice of τc = 1 h guarantees a safe con-
troller action with moderate glucose concentration maximum values.
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Figure 4.18: Post-prandial responses to three meals.The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).4.2. VALIDATION TEST: POST-PRANDIAL RESULTS 63
Table 4.8: Single meal statistics: percentage of time that the glucose concentration
remains within the indicated range.
Subject 60<G<80 80<G<140 70<G<180 180<G<250 G>250
1 0 32 68 26 6
2 0 44 91 9 0
3 0 82 100 0 0
4 0 46 92 8 0
5 0 27 70 31 0
6 7 45 65 27 8
7 0 40 84 17 0
8 0 45 84 16 0
9 3 65 100 0 0
10 6 51 74 25 2
mean(±std) 1.6(± 2.7) 48 (±15) 83(±12) 16 (±11) 2( ± 3)
Table 4.9: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal.
Subject dinner breakfast lunch
1 130 104 108
2 62 51 56
3 38 33 34
4 56 51 36
5 96 74 56
6 149 118 97
7 64 51 44
8 73 58 57
9 28 42 21
10 123 99 86
mean 82 68 59
±std ± 39 ± 28 ± 2764 4. CONTROLLER WITH A NON-PERSONALIZED CONTROLLER GAIN
Table 4.10: Time to return to the normo-glycemia zone after the meal.
Subject dinner breakfast lunch
1 6.8 h 4.7 h 4.7 h
2 5.0 4.0 3.9
3 4.3 0.0 2.0
4 5.4 4.1 4.0
5 7.3 / 5.3
6 6.1 4.9 4.7
7 7.3 / 6.4
8 6.7 / 5.6
9 4.8 0.0 0.0
10 5.7 4.5 4.5
Table 4.11: Blood glucose (mg/dl) maximum (Gmax) and minimum (Gmin) glucose
values during the post-prandial response.
Subject Gmin Gmax
1 84 279
2 112 204
3 92 168
4 90 195
5 88 245
6 70 282
7 112 199
8 111 211
9 79 171
10 72 252
mean 91 220
±std ± 15 ± 39Chapter 5
Controllers With a Personalized
Controller Gain
The structure fo this chapter is the same as Chapter 4. The same population
of ten subjects from the UVA/Padova metabolic simulator used in Chapter 4
Section 4.1 is used to investigate the best tuning of the PID controller, when
the controller gains are personalized. Then, the diﬀerent population used for the
validation test in Chapter 4 is used to validate the selected controller tuning. The
mean results for all the simulations conducted are reported in this chapter, and
in Appendix all the single subject results are reported as well.
5.1 Eect of τc
In this section the results of the controller tuning are reported. The controller
gain is now personalized for each subject based on the TDI value. The controller
gain Kc in Eq. (3.14) depends either on the process model gain (K) and on the
desired speed-of-response time constant τc. Table 5.1 reports the process model
personalized gains.The model gains can be personalized either using the subjects’
TDI, or by determining the process gain for each subject with a step test as
explained in Appendix B. However, the use of only TDI information is the better
way to personalize the gain, since it is a priori information provided by physicians.
In Table 5.1, the gain calculated by the step test are reported as well, to provide a66 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
comparison between the two types of gain calculations. Both TDI based gains and
step-test gains are between - 4.2 and -0.67 (mg/dl/pmol/min), which are smaller
than the ﬁxed gain used by van Hausden [1] -8.13 (mg/dl/pmol/min). Indeed,
the ﬁxed gain was chosen to lead to a robust and conservative controller rather
than an aggressive one, since the controller output is inversely proportional to the
model gain. These relationships can be veriﬁed in Table 5.2 where the personalized
with TDI information and non personalized controller gains for τc = 1,2,3,4 and
5 h are reported.
The same population of Chapter 4 is used to conduct simulations in order to
evaluate the eﬀect of τc on the controller performance for post-prandial conditions.
The scenario chosen for the controller tuning is:
• t=2 h: controller turned on;
• t=7 h: a single meal of 50 g CHO is given;
• t=30 h: simulation ends.
The controller set point is 110 mg/dl for all the subjects. The simulation lasts
30 h in order to observe the entire response and determine whether or not the
set point is reached for the critical case of undershoot and hypoglycemia. Based
on the FOPTD model in Eq. (3.9) and on the more aggressive model gains, ﬁve
values of τc were considered: τc = 1, 2, 3, 4 and 5 h.
The simulation results for the three diﬀerent values of τc are reported in
Figures 5.1- 5.5 and Tables 5.3 and 5.4. For τc = 1 h the personalized controller
is too aggressive, since, on average, 3(±3)% of the time the glucose concentration
is within the range 60-80 mg/dl, and all the subjects exhibit undershoot more or
less marked (subjects ♯ 6,7 and 9 show the largest undershoots). However, for none
of the τc values considered show hypoglycemia or hyperglycemia events. Similar
results are obtained for τc = 2 h, even though the undershoots are reduced; only
subjects ♯ 6 and 9 are below 80 mg/dl, and in particular only subject ♯ 9 is below
the normo-glycemia lower bound for a considerable percentage of time (20%). A
relevant improvement in the controller performance is achieved for τc = 3 h, since
only subject ♯ 9 shows a glucose concentration below 80 mg/dl, and for only 85.1. EFFECT OF τC 67
Table 5.1: Process gains calculations (mg/dl/pmol/min) with step changes calcu-
lated in Appendix B and TDI.∗
Subject TDI Step test
1 -2.38 -1.29
2 -2.07 -1.04
3 -2.13 -1.37
4 -3.55 -3.65
5 -1.76 -0.67
6 -1.95 -2.84
7 -2.86 -4.18
8 -2.81 -1.51
9 -1.79 -1.00
10 -1.86 -0.98
* Van Hausden’s gain -8.13
Table 5.2: Personalized controller gains Kc (pmol/min/mg/dl)
Subject τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
1 -1.25 -0.90 -0.70 -0.58 -0.49
2 -1.44 -1.03 -0.81 -0.66 -0.56
3 -1.40 -1.01 -0.79 -0.65 -0.55
4 -0.84 -0.60 -0.47 -0.39 -0.33
5 -1.70 -1.22 -0.95 -0.78 -0.66
6 -1.53 -1.10 -0.86 -0.70 -0.60
7 -1.04 -0.75 -0.59 -0.48 -0.41
8 -1.06 -0.76 -0.60 -0.49 -0.41
9 -1.67 -1.20 -0.94 -0.77 -0.65
10 -1.60 -1.15 -0.90 -0.74 -0.63
Van Hausden -0.37 -0.26 -0.21 -0.17 -0.14
% of the time. The less aggressive controller action for τc = 3 h results in higher
values of ∆G, Gmax, Gmin and tr, but still guarantees a good performance. For
τc = 4 and 5 h, the controller aggressiveness is further reduced, resulting in no
subjects with glucose concentration in the range 60-80 mg/dl, but increasing the
percentage of time in the range 60-80 mg/dl 11(±5)% for τc = 5 h.68 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
In Figures 5.6 and 5.7 the eﬀect of the ﬁve τc values for subjects ♯ 5 and 9 is
showed. Subject ♯ 9 shows the most undershoot for all ten subjects. Comparing
the controller action for τc = 1 h and τc = 3 h, it can be observed that the better
trade-oﬀ between speed of response and undershoot occurs for τc = 3 h where the
undershoot remains above 80 mg/dl and time to return in the normo-glycemia
zone is 5.2 (±5) %.
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Figure 5.1: Post-prandial responses for τc = 1 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-gyicemia
zone (80-140 mg/dl).5.1. EFFECT OF τC 69
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Figure 5.2: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glycemia
zone (80-140 mg/dl).
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Figure 5.3: Post-prandial responses for τc = 3 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).70 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
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Figure 5.4: Post-prandial responses for τc = 4 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glycemia
zone (80-140 mg/dl).
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Figure 5.5: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glycemia
zone (80-140 mg/dl).5.1. EFFECT OF τC 71
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Figure 5.6: Post-prandial responses for subject ♯ 5 and diﬀerent τc. The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glycemia zone (80-140 mg/dl).
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Figure 5.7: Post-prandial responses for subject ♯ 9 and diﬀerent τc. The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glycemia zone (80-140 mg/dl).72 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
Table 5.3: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects.
range τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
60<G<80 3 (± 7) 3 (± 6) 1 (± 2) 0 0
80<G<140 75 (± 13) 73 (± 13) 72 (± 12) 71 (± 11) 70 (± 11)
70<G<180 95 (± 7) 94 (± 4) 93 (± 4) 91 (± 5) 90 (± 5)
180<G<250 4 (± 4) 6 (± 5) 8 (± 5) 10 (± 5) 11 (± 5)
Table 5.4: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax−Gmeal. Gmax is the maximum blood glucose value and Gmin is the minimum
value, during the post-prandial response. tr is the time to return to the normo-
glycemia zone after the meal.
metrics τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
∆G (mg/dl) 46 (± 16) 52 (± 17) 57 (± 18) 61 (± 19) 64 (± 19)
Gmax (mg/dl) 187 (± 16) 194 (± 17) 199 (± 18) 202 (± 19) 199 (± 18)
Gmin (mg/dl) 85 (± 9) 90 (± 8) 94 (± 8) 94 (± 8) 94 (± 8)
tr (h) 4.2 (± 1.2) 4.7 (± 1.3) 5.2 (± 1.4) 55 (± 1.4) 5.8 (± 1.5)5.1. EFFECT OF τC 73
5.1.1 Robustness Test
In order to verify the controller behavior for intra-subject changes of ±50% in the
insulin sensitivity, as explained in Chapter 4, the controller output was reduced
or increased by 50%. In this case, the robustness test can also give information
about the controller performance, when the actual subject’s TDI value diﬀers
from the TDI estimated by the 2400 rule Eq. (3.3). The robustness test results
with the controller output changes by ±50% are reported for each τc value in-
vestigated, except for τc = 1 h, because the performance was already poor for
normal conditions.
τc = 2 h
Robustness results for τc = 2 h are reported in Figures 5.8 - 5.11. When the
controller output is increased by 50%, all post-prandial responses result in more
oscillatory behavior, with really large undershoots especially for subject ♯ 9.
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Figure 5.8: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glycemia
zone (80-140 mg/dl).The controller output is reduced by 50%.74 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
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Figure 5.9: Post-prandial responses for τc = 2 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.
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Figure 5.10: Post-prandial responses for subject ♯ 5, τc = 2 h and the three con-
troller output conditions(normal, increase bye 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glycemia zone (80-140 mg/dl).5.1. EFFECT OF τC 75
0 5 10 15 20 25 30
60
80
110
140
160
190
220
250
Time [h]
G
l
u
c
o
s
e
 
[
m
g
/
d
l
]
 
 
0 5 10 15 20 25 30
1
2
3
4
5
Time [h]
I
n
s
u
l
i
n
 
[
U
/
h
]
 
 
normal
−50%
+50%
normal
−50%
+50%
Figure 5.11: Post-prandial responses for subject ♯ 9, τc = 2 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
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τc = 3 h
Robustness results for τc=3 h are reported in Figures 5.12 - 5.15. When the
controller is increased by 50%, the post-prandial response still show signiﬁcant
undershoots, but no hypoglycemic events occur.
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Figure 5.12: Post-prandial responses for τc = 3 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.
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Figure 5.13: Post-prandial responses for τc = 3 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is increased by 50%5.1. EFFECT OF τC 77
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Figure 5.14: Post-prandial responses for subject ♯ 5, τc = 3 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).
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Figure 5.15: Post-prandial responses for subject ♯ 9, τc = 3 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).78 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
τc = 4 h
Robustness results for τc = 4 h are reported in Figures 5.16 - 5.19, and the only
subject that show a relevant undershoot when the controller output is increased
by 50% is ♯ 9, since its response is below the normo-glycemia undershoot.
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Figure 5.16: Post-prandial responses for τc = 4 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.
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Figure 5.17: Post-prandial responses for τc = 4 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is increased by 50%5.1. EFFECT OF τC 79
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Figure 5.18: Post-prandial responses for subject ♯ 5, τc = 4 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).
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Figure 5.19: Post-prandial responses for subject ♯ 9, τc = 4 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).80 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
τc = 5 h
Robustness results for τc=5 h are reported in Figures 5.20 - 5.23, the controller
performance is similar to the one for τc=4 h
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Figure 5.20: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is reduced by 50%.
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Figure 5.21: Post-prandial responses for τc = 5 h. The thick dashed line indicates
the set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).The controller output is increased by 50%5.1. EFFECT OF τC 81
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Figure 5.22: Post-prandial responses for subject ♯ 5, τc = 5 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).
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Figure 5.23: Post-prandial responses for subject ♯ 9, τc = 5 h and the three con-
troller output conditions (normal, increase by 50% and decrease by 50%). The
thick dashed line indicates the set point (110 mg/dl). The two thin dashed lines
indicate the normo-glyciemia zone (80-140 mg/dl).82 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
In Tables 5.5-5.8 the robustness results for diﬀerent τc values are reported in
terms of means and standard deviations. When the controller output is increased
by 50%, for τc = 2 h,the glucose concentration remains in the hypoglycemia zone
0.9(±2.7)% of the time, demonstrating that the controller is robust. For τc = 3,
4 and 5 h, there are no cases of hypoglycemia, even when the controller output is
increased by 50%. The percentage of time in the other ranges are similar for τc =
3, 4 and 5 h, but for τc = 3, 3(±3)% of the time, glucose concentration is in the
range 180-250, whereas for τc = 5 h the time in the same range is 5(±5)% of the
rime. In general τc = 3 h performed the best compared to the other τc values, e.g
tr is equal to 3.9(±1.2) instead of 4.6(±1.3) for τc= 5 h, still avoiding the risk of
hypoglycemia.
When the controller output is reduced by 50%, the percentage of time in the
range 180-250 is increased, and for τc = 5 h it reaches the average of 13(±5)%.
For τc = 3 h the percentage of time in the same glucose zone is reduced and at
the same time, good performance is guaranteed even with the more conservative
controller, since the highest glucose value is 207 (± 19).
Table 5.5: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects,
when the controller output is increased by 50%.
range τc = 2 h τc = 3 h τc = 4 h τc = 5 h
G<60 0.9 (± 2.7) 0 0 0
60<G<80 3 (± 5) 3 (± 7) 3 (± 7) 3 (± 7)
80<G<140 76 (± 12) 76 (± 13) 74 (± 14) 73 (± 14)
70<G<180 96 (± 6) 96 (± 7) 95 (± 7) 95 (± 5)
180<G<250 2 (± 2) 3 (± 3) 4 (± 5) 5 (± 5)5.1. EFFECT OF τC 83
Table 5.6: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax−Gmeal. Gmax is the highest blood glucose value and Gmin is the lowest value,
during the post-prandial response. tr is the time to return to the normo-glycemia
zone after the meal. The controller output is increased by 50%
metrics τc = 2 h τc = 3 h τc = 4 h τc = 5 h
∆G (mg/dl) 40 (± 16) 43 (± 16) 46 (± 16) 50 (± 17)
Gmax (mg/dl) 182 (± 16) 185 (± 16) 189 (± 16) 192 (± 17)
Gmin (mg/dl) 81 (± 11) 84 (± 10) 87 (± 9) 89 (± 8)
tr (h) 3.6 (± 1.2) 3.9 (± 1.2) 4.3 (± 1.2) 4.6 (± 1.3)
Table 5.7: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects,
when the controller output is decreased by 50%
range τc = 2 h τc = 3 h τc = 4 h τc = 5 h
60<G<80 0 0 0 0
80<G<140 71 (± 11) 69 (± 12) 67 (± 12) 65 (± 12)
70<G<180 91 (± 5) 89 (± 5) 88 (± 5) 88 (± 5)
180<G<250 9 (± 5) 11 (± 5) 12 (± 5) 13 (± 5)
Table 5.8: Single meal statistics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax − Gmeal. Gmax is the maximum blood glucose value. Gmin is the minimum
value. tr is the time to return to the normo-glycemia zone after the meal. the
controller output is decreased by 50%.
metrics τc = 2 h τc = 3 h τc = 4 h τc = 5 h
∆G (mg/dl) 60 (± 19) 64 (± 20) 68 (± 20) 71 (±21)
Gmax (mg/dl) 202 (± 19) 207 (± 19) 210 (± 20) 213 (±21)
Gmin (mg/dl) 96 (± 8) 100 (± 8) 102 (± 8) 105 (±20)
tr (h) 5.5 (± 1.4) 5.9 (± 1.5) 6.3 (± 1.6) 6.6 (±1.6)84 5. CONTROLLERS WITH A PERSONALIZED CONTROLLER GAIN
5.1.2 Discussion
Both the results of the eﬀect of the τc values and the robustness test show the best
PID tuning settings results when τc = 3 h. Indeed, no cases of hypo- or hyper-
glycemia occurred for the three controller conditions (normal, ±50%). Moreover
96(±7)% of the time the glucose concentration remains within the range 70-180;
in particular subjects ♯ 1, 2, 3, 7, and 8 remain in that range for 100 % of the time.
The highest glucose concentration value,among all the subjects, is 235 mg/dl for
subject ♯ 4 when the controller output is decreased by 50%; the lowest glucose
concentration value is 61 mg/dl when the controller output is increased by 50%.
5.2 Validation Test: Post-prandial Results
After analyzing the eﬀect of τc and concluding that the best controller perfor-
mance is achieved for τc = 3 h, a validation test is conducted, as in Chapter 4.
The same population from the UVA/Padova metabolic simulator that was used
for the validation test of the non-personalized gain is used here. Again a three
meal challenge (dinner, breakfast and lunch) is evaluated. The validation test
scenario is:
• t=0 h (1 pm): simulation starts
• t=2 h (3 pm): controller turned on;
• t=5 h (8 pm): a meal of 50 g CHO (dinner) is given;
• t=16 h (7 am): meal of 40 g CHO (breakfast) is given;
• t=21 h (12 pm): meal of 50 g CHO (lunch) is given;
• t=30 h (9 pm): simulation ends.
Figure 5.24 and Tables 5.9-5.12 show the validation test results. The ﬁrst
important result is that none of the subjects exhibited cases of hypoglycemia.
Nevertheless, the lowest value of the glucose concentration detected is 60 mg/dl
for subject ♯ 6 , extremely close to the hypoglycemia zone; however, this low5.2. VALIDATION TEST: POST-PRANDIAL RESULTS 85
glucose level occurs around 9 pm, when another meal is supposed to be given.
The percentage of time in the range 70-180 is 88(±11)% and in particular it is
100% for subjects ♯ 3 and 9. After the meal intake, the time to return to the
normo-glycemia for all the subjects is below 6.2 h, and the glucose concentration
of subject ♯ 9, after the ﬁrst meal, remains in the normo-glycemia zone for the
entire simulation. The highest glucose concentration excursions, due to the meals,
occur after the the ﬁrst meal (dinner), and The average maximum excursion is
of 73(±34) mg/dl (the highest value is 130 mg/dl for subject ♯ 6). After the
other meals, it gradually decreases to 60 (±28) mg/dl. The maximum value of
the glucose concentration is 260 mg/dl for subject ♯ 6, with an average for the 10
subjects of 208(±34) mg/dl. hyperglycemia only for 0.8(±1.7)% of time. These
results demonstrate that the choice of τc= 3 h guarantees a safe controller action
with moderate peak values.
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Figure 5.24: Post-prandial responses to three meals.The thick dotted line indicates
the set point (110 mg/dl). The two dotted lines indicate the normo-glyciemia zone
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Table 5.9: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range.
Subject G<60 60<G<80 80<G<140 70<G<180 180<G<250 G>250
1 0 9 40 79 18 3
2 0 0 53 95 6 0
3 0 0 87 100 0 0
4 0 0 54 94 6 0
5 0 4 36 86 14 0
6 0 16 47 64 21 5
7 0 0 58 94 6 0
8 0 0 65 92 8 0
9 0 0 77 100 0 0
10 0 11 55 73 19 0
mean 0 4 (±6) 57(±15) 88(±11) 10(±7) 1(±2)
Table 5.10: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal.
Subject dinner breakfast lunch
1 118 102 114
2 60 50 57
3 37 33 35
4 53 50 37
5 79 73 55
6 130 111 99
7 59 49 42
8 70 58 57
9 20 39 21
10 109 96 88
mean 73 66 60
std ±34 ±26 ±295.2. VALIDATION TEST: POST-PRANDIAL RESULTS 87
Table 5.11: Time to return to the normo-glycemia zone after the meal.
Subject dinner breakfast lunch
1 4.5 h 3.6 h 3.6 h
2 4.3 3.1 3.1
3 3.6 / 1.6
4 4.9 3.5 3.3
5 5.6 4.5 4.5
6 4.7 4.1 4.0
7 6.2 3.9 4.1
8 5.6 3.3 3.2
9 2.9 / /
10 4.6 3.9 3.8
Table 5.12: Maximum ( Gmax) and minimum (Gmin) glucose concentration
(mg/dl) values during the post-prandial response.
Subject Gmin Gmax
1 76 259
2 107 200
3 92 164
4 87 190
5 76 222
6 60 260
7 95 192
8 98 205
9 82 155
10 67 238
mean 84 208
std ±14 ±34Chapter 6
Comparison of The Controllers
Performance
In this chapter a direct comparison between the results obtained with the non-
personalized controller and the personalized controller are presented. In partic-
ular, ﬁgures and tables of the single meal post-prandial responses for both the
ﬁnal controllers with the selected settings are reported along with the robustness
test when the insulin sensitivity is increased by 50%. The validation test results
for the three meal, 30 hours scenario are also included.
6.1 Normal output
Figures 6.1-6.6 and Tables 6.1 and 6.2 show the results for the personalized and
non-personalized controllers with the selected settings, for the post-prandial re-
sponse simulations in Chapter 4 and Chapter 5 and a single meal of 50 g of CHO.
With a personalization of the controller the percentage of time in the range 70-180
results is considerably improved compared to the non-personalized controller, in-
creasing from 88 (± 6)% to 93 (±4)%. Also the time in the normo-glycemia range
improves from 66(±13)% for the non-personalized controller to 72 (±13)% after
introducing the personalization. The personalized controllers reduce the highest
peak from 212 (± 21) mg/dl to 199 (±18) mg/dl, as well as the time to return in
the normo-glycemia zone after the meal (from 6.5 (± 1.8) h to 5.2(±1.2) h). The90 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
single subject ﬁgures show that the personalized controller is in general more
aggressive than the non-personalized, but the aggressiveness results in glucose
concentration values that are lower and a faster response leading to a better per-
formance, e.g subject ♯ 5; on the other hand, the controller personalization often
increases the undershoots, but never below the normo-glycemia zone (subject ♯
6,9 and 10).
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Figure 6.1: Post-prandial responses with a non-personalized controller. The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glyciemia zone (80-140 mg/dl).6.1. NORMAL OUTPUT 91
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Figure 6.2: Post-prandial responses with a personalized controller. The thick
dashed line indicates the set point (110 mg/dl). The two thin dashed lines indicate
the normo-glyciemia zone (80-140 mg/dl).
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Figure 6.3: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 5. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).92 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
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Figure 6.4: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 6. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).
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Figure 6.5: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 9. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).6.1. NORMAL OUTPUT 93
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Figure 6.6: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 10. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).
Table 6.1: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects.
np=non-personalized gain, p=personalized gains
range np p
60<G<80 0 (±5) 1 (±2)
80<G<140 66 (±13) 72 (±13)
70<G<180 88 (±6) 93 (±4)
180<G<250 12 (±6) 8 (±5)94 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
Table 6.2: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax−Gmeal. Gmax is the highest blood glucose value and Gmin is the lowest value,
during the post-prandial response. tr is the time to return to the normo-glycemia
zone after the meal. np=non-personalized gain, p=personalized gains
metrics np p
∆G (mg/dl) 69 (±22) 57 (±18)
Gmax (mg/dl) 212 (±21) 199 (±18)
Gmin (mg/dl) 104 (±9) 94 (±18)
tr (h) 6.5 (±1.8) 5.2 (±1.2)
6.2 Controller output increased of the 50%
In Figures 6.7-6.10 the comparison between personalized and non-personalized
controllers performances for some subjects is reported, when the insulin sensitiv-
ity is increased by 50%. When the insulin sensitivity increases, the personalized
controller provides a more oscillatory post-prandial response, but only for subject
♯ 9 the performance of the personalized controller is much worse than the non-
personalized, since the undershoot is quite close to 60 mg/dl. But on the other
hand the higher glucose concentration values are considerably reduced.
Tables 6.3 and 6.4 compare personalized and non-personalized controller per-
formances. For the non-personalized controller, none of the subjects spend time in
the range 60-80 mg/dl when the insulin sensitivity is 50% higher, but for 3(±7)%
of the time the glucose concentration is in that range for the personalized con-
troller. However, all the other metrics provide better results when a controller
personalization is performed.6.2. CONTROLLER OUTPUT INCREASED OF THE 50% 95
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Figure 6.7: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 5. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.
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Figure 6.8: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 6. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.96 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
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Figure 6.9: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 9. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.
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Figure 6.10: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 10. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl). The controller output is increased by 50%.6.2. CONTROLLER OUTPUT INCREASED OF THE 50% 97
Table 6.3: Single meal statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects.
np=non-personalized gain, p=personalized gains
range np p
60<G<80 0 (±5) 3 (±7)
80<G<140 73 (±12) 76 (±13)
70<G<180 92 (±5) 96 (±7)
180<G<250 8 (±5) 3 (±3)
Table 6.4: Single meal metrics: mean and standard deviation for each τc value.
∆G is the glucose peak value relative to the value tmeal, the meal time: ∆G =
Gmax−Gmeal. Gmax is the highest blood glucose value and Gmin is the lowest value,
during the post-prandial response. tr is the time to return to the normo-glycemia
zone after the meal. np=non-personalized gain, p=personalized gains.
metrics np p
∆G (mg/dl) 57(±20) 43 (±16)
Gmax (mg/dl) 199 (±19) 185 (±16)
Gmin (mg/dl) 95 (±8) 84 (±10)
tr (h) 5.1 (±1.5) 3.9 (±1.2)98 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
6.3 Validation test
Figures 6.11 and 6.12 show the non-personalized and personalized controllers
performances, respectively, in the validation test presented in Chapters 4 and
5. Figures 6.13-6.16 show the comparison between the personalized and non-
personalized controllers for the three meal test, whereas Tables 6.5 and 6.6 com-
pare the numerical results. For both the personalized and non-personalized con-
trollers, there are no cases of hypoglycemia, but the personalized controller is
able to maintain the subjects in the normo-glycemia zone for 57(±15)% and for
88(±)% in the range 70-180 mg/dl, while for the non-personalized controller the
percentage of time in the normo-glycemia zone is 48(±15)% and 83(±12)% in
the range 70-180 mg/dl. All the other metrics show that the best performance
is achieved with the personalized controller, since the post-prandial glucose con-
centration peak after the meal intake is reduced for all the subjects and never
results in hypoglycemia.
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Figure 6.11: Post-prandial responses to three meals with a non-personalized con-
troller. The thick dashed line indicates the set point (110 mg/dl). The two thin
dashed lines indicate the normo-glyciemia zone (80-140 mg/dl).6.3. VALIDATION TEST 99
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Figure 6.12: Post-prandial responses to three meals with a personalized controller.
The thick dashed line indicates the set point (110 mg/dl). The two thin dashed
lines indicate the normo-glyciemia zone (80-140 mg/dl).
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Figure 6.13: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 1. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).100 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
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Figure 6.14: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 5. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).
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Figure 6.15: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 6. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).6.3. VALIDATION TEST 101
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Figure 6.16: Post-prandial responses comparison for personalized (p) and non-
personalized controllers (np) for subject ♯ 8. The thick dashed line indicates the
set point (110 mg/dl). The two thin dashed lines indicate the normo-glyciemia
zone (80-140 mg/dl).
Table 6.5: One day statistics: percentage of time that glucose concentration
(mg/dl) remains within the indicated range. Average values for the ten subjects.
np=non-personalized gain, p=personalized gains
range np p
G < 60 0 0
60<G<80 2 (±5) 4 (±6)
80<G<140 48 (±15) 57 (±15)
70<G<180 83 (±12) 88 (±11)
180<G<250 16 (±11) 10 (±7)
G > 250 2 (±3) 1 (±2)102 6. COMPARISON OF THE CONTROLLERS PERFORMANCE
Table 6.6: Single meal metrics: mean and standard deviation for each τc value.
∆Gmax is the maximum glucose peak value relative to the value tmeal, the meal
time: ∆G = Gmax − Gmeal. Gmax is the maximum blood glucose value and Gmin
is the minimum value, during the post-prandial response. np=non-personalized
gain, p=personalized gains.
metrics np p
∆Gmax (mg/dl) 82(±39) 73 (±40)
Gmax (mg/dl) 220 (±39) 208 (±34)
Gmin (mg/dl) 91 (±15) 84 (±14)Conclusion
The aim of this work was to develop a novel and robust PID control algorithm
to control the glucose concentration in people with type 1 dabetes mellitus . A
discrete third-order control-relevant model (van Hausden et al. [1]) was approxi-
mated to a continuous, second-order plus time delay model. The model gain can
be either personalized with the subject TDI or be ﬁxed. Then, this continuous
model was used for the PID algorithm designed based on the IMC approach.
With this approach the three PID tuning settings were calculated on the basis
of the process dynamics and the model gain and they were reduced to a single
adjustable parameter (τc).
Two types of controllers were implemented:(i) a non-personalized controller
(with a ﬁxed model gain) and (ii) a personalized controller (with a model gain
based on the subject TDI). The investigation of the best τc value for both the
controllers was conducted in silico with a population of ten subjects of the
UVA/Padova metabolic simulator. The ten simulated subjects were used to deter-
mine a conservative value τc . This value provided good post-prandial responses
and a reasonable degree of robustness for changes of+/- 50% in the insulin sen-
sitivity. Then ten additional subjects were simulated in a validation study that
included three meals (50, 40 and 50 g CHO) during a 30 hour period. For the
validation study, the average amount of time that the glucose concentration was
in the desired range (70-180 mg/dl) was 88% for the personalized controller and
83% for the non-personalized. Similarly, the average values for the 180-250 mg/dl
range were 10% and 16% for the personalized and ﬁxed controllers, respectively.
Neither design method resulted in hypoglycemia (<60 mg/dl).
These results show that the controllers designed are both robust, but that104 CONCLUSION
the personalized controllers performance is superior to the non-personalized con-
trollers. Therefore, in the future only the personalized controller should be con-
sider. Moreover, further tests should be performed, e.g. robustness test for three
unannounced meals and more days of simulations (3-4 days) in order to see the
controller behavior for a longer period. Simulations with the controller and insulin
bolus should be conducted to see the controller responses for the bolus, as well.
A risk of the both implemented PID controllers is the long undershoot that can
occurs after the meal. The undershoot is mostly due to the integral action of the
controller. Thus, an improvement in the controller can be obtained by limiting
the integral action with upper and lower constraints.Appendix A
The UVA/Padova Metabolic
Simulator
In January 2008 the UVA/Padova Metabolic simulator was accepted by the Food
and Drug Administration (FDA) to replace the classic preclinical procedure of
animal trials in order to test closed-loop control strategies. The main motivation
is that the results obtained by the modeling are as credible as the results obtained
in the clinical trials, and at the same time much faster [28]. However, a control
algorithm tested in silico can perform in a diﬀerent way in vivo, for this reason
a simulation only is considered as a preliminary step to test extreme situations
and the general performance of the algorithm. The schematic overview of the
UVA/Padova metabolic simulator in Figure A.1 and consists of three main parts:
in silico subject, in silico sensor and in silico pump [28].
A.1 Model Development
In silico Subject
The in silico subject is modeled with diﬀerent subsystems. The glucose subsys-
tem is a two-compartment model of the glucose kinetics: the ﬁrst compartment
models the insulin-independent utilization (plasma and fast equilibrating tissues),
the second compartment models the insulin-dependent utilization (peripheral tis-
sues). The insulin subsystem is also composed of two compartments: the ﬁrst106 APPENDIX
Figure A.1: Scheme of the glucose-insulin control system. the dashed line stands
for control signals and continuous lines represents ﬂuxes of materials [29].
models the liver and the second the plasma [28, 29, 30].
The processed unit of glucose and insulin subsystems are endogenous glucose
production, glucose rate of appearance, glucose utilization and insulin secretion.
Their models were identiﬁed using a forcing function strategy. The interruption
of the endogenous glucose production is assumed to be linearly dependent on
plasma glucose concentration, portal insulin concentration and delayed insulin
signal. Glucose rate of appearance is obtained by a physiological model of glucose
intestinal absorption. The glucose transit through the stomach and intestine is
modeled by two compartments for the stomach (one for the solid phase and one
for the triturated phase) and one compartment for the gut. Glucose utilization is
assumed to consists of two compartments: one for the insulin-independent (brain
and erythrocytes) and it is constant, the second for the insulin-dependent utiliza-A.1. MODEL DEVELOPMENT 107
Figure A.2: Unit process models [30]. The entering arrows represents forcing func-
tion variables and the outgoing arrows are model output.
tion and is nonlinearly dependent from glucose in the tissues and it occurs in a
remote compartment [28, 29, 30].
In order to simulate type 1 diabetic subject the insulin secretion module is
substituted by a subcutaneous insulin module. The model has 26 free parameters
and the most important are hepatic and peripheral insulin sensitivity.
In silico Sensor
The in silico sensors are based on the analysis of sensor errors. CGM technology
unfortunately has still to improve in terms of sensitivity, stability, calibration
and the physiological time lag between blood and interstitial glucose concen-
tration. The sensor errors is decomposed into errors due to calibration, blood-
to-interstitial glucose transfer and random noise. The sensor simulation model
provides the worst-case scenario sensor errors and they are described by Breton
and Kovatchev [31].108 APPENDIX
In silico Insulin Pump
The in silico insulin pump approximates the subcutaneous insulin delivery, mim-
icking time and dynamics of insulin transport from subcutaneous tissues into
blood. Furthermore, the insulin is delivered by a stepwise basal pump rate and
insulin boluses, providing discrete insulin infusion [28].
A.2 Software
The models described above are implemented into a computerized platform using
Simulink R ⃝ (part of the scientiﬁc software Matlab R ⃝). The user can run the
simulations by an user interface window of the software. Figure A.3 shows the
user interface in which it is possible to choose the scenario, the subjects, where
also subgroups can be selected, and some outcome metrics [28].
During the simulation it is possible to have access to some patients charac-
teristics, since these characteristics can be obtained by a screening visit of the
patient. This information is:
a) name;
b) weight, in Kg;
c) the patient fasting blood glucose concentration in mg/dl;
d) the insulin rate in U/h;
e) the optimum bolus in U/g of carbohydrates;
f) the maximum drop in mg/dl per Units of insulin;
g) the avarage total daily insulin regimen in Units of insulin.A.2. SOFTWARE 109
Figure A.3: Simulator user interface [30].Appendix B
Step Response Test
For each subject of the simulator it is possible calculate the process gain by ﬁtting
the glucose responses to a ﬁrst-order-plus-time delay (FOPTD) model. Indeed,
the process gain K of the FOPTD model for each subject in the simulator can
be obtained by calculating the slope of the line which approximates two or more
points (a regression line) obtained by the basal insulin values changes and the
corresponding steady-state glucose changes [19].
For each subject three open-loop simulations were conducted, Figure B.1.
One simulation was conducted with the normal basal insulin, the second with a
decrease in the basal insulin of 0.1 U/h, and the third with an increase in the
basal insulin of 0.1 U/h. For each kind of basal insulin input (normal, low and
high) the three correspondent glucose steady-state conditions were measured. In
table Table B.1 the three inputs for each subject are reported and in Table B.2
the corresponding outputs.112 APPENDIX
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Figure B.1: Open-loop responses to the normal basal insulin for ten subjects of
the UVA/Padova simulatorAPPENDIX 113
Table B.1: Three diﬀerent basal insulin conditions (pmol/min).
Subject Regular Low High
1 127 117 137
2 137 127 147
3 143 133 153
4 89 79 99
5 118 108 128
6 172 162 182
7 137 127 147
8 114 104 124
9 113 103 123
10 102 92 112
Table B.2: Steady-state glucose values (mg/dl) corresponding to the three condi-
tions of basal insulin
Subject Regular Low High
1 141 154 128
2 138 149 128
3 144 158 131
4 146 189 117
5 141 148 135
6 142 174 117
7 144 194 111
8 142 158 127
9 143 154 134
10 154 165 145114 APPENDIX
The three input/output conditions for each subject i (xil,yil) for l=1,2 and 3
were used to calculate the regression line for each subject [32]:
yi = mxi + q (B.1)
yi is the glucose values at the steady state (mg/d) for subject i
xi is the basal insulin (pmol/min) for subject i.
Minimizing the residual sum of squares for each subject [32] gives:
S(m,q) =
n ∑
l=1
(mxl + q − yl)
2 (B.2)
(B.3)
m =
∑n
l=1 xiyi − n¯ x¯ y
∑n
l=1 x2
i − n¯ x2 (B.4)
The slope of each regression line m (mg/dl/pmol/min) provides the gain of
each subject which are reported in Table B.3.
Table B.3: Gain (mg/dl/pmol/min)
Subject Gain
1 -1.29
2 -1.04
3 -1.37
4 -3.65
5 -0.67
6 -2.84
7 -4.18
8 -1.51
9 -1.00
10 -0.98
mean -1.85Appendix C
Non-personalized Model Gain
Results
The results for all the subjects with the non-personalized controller are reported
in this chapter along with the robustness results.
Table C.1: Single meal statistics: percentage of time that the glucose concentration
remains within the indicated range for τc= 1 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 76 86 15
2 0 80 91 10
3 0 60 85 15
4 0 69 91 9
5 0 54 84 16
6 0 78 86 15
7 0 86 94 6
8 0 59 100 0
9 0 47 79 21
10 0 52 83 17
mean (±std) 0 66 (±13) 88 (±6) 12 (±6)116 APPENDIX
Table C.2: Single meal statistics: percentage of time that glucose concentration
remains within the indicated range for τc= 2 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 73 85 16
2 0 78 89 11
3 0 57 84 17
4 0 65 88 12
5 0 50 83 17
6 0 74 83 17
7 0 84 91 9
8 0 55 100 0
9 0 44 78 22
10 0 48 82 18
mean (±std) 0 63 (±13) 86 (±6) 14 (±6)
Table C.3: SSingle meal statistics: percentage of time that glucose concentration
remains within the indicated range for τc= 5 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 68 83 17
2 0 75 88 12
3 0 48 81 19
4 0 53 85 15
5 0 41 81 19
6 0 66 79 21
7 0 79 88 12
8 0 47 95 5
9 0 38 76 24
10 0 39 79 18
mean (±std) 0 55 (±15) 84 (±5) 16 (±5)APPENDIX 117
Table C.4: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal.
Subject τc = 1 h τc = 2 h τc = 5 h
1 62 66 71
2 62 67 70
3 57 69 84
4 81 87 99
5 63 66 72
6 97 107 114
7 58 65 77
8 23 27 31
9 101 107 113
10 88 93 99
mean (±std) 69 (±22) 75 (±23) 83 (±24)
Table C.5: Time to return to the normo-glycemia zone after the meal.
Subject τc = 1 h τc = 2 h τc = 5 h
1 7.6 h 8.4 h 9.8 h
2 6.5 7.1 8.1
3 6.6 7.2 8.8
4 4.8 5.4 7.1
5 8.2 9.0 10.7
6 7.1 8.3 10.6
7 4.8 5.4 6.8
8 7.4 8.0 9.1
9 9.0 9.8 11.6
10 7.6 8.6 11.4
mean (±std) 6.5 (±1.8) 7.2 (±1.9) 8.7 (±2.3)118 APPENDIX
Table C.6: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) values.
Gmax Gmin
Subject τc = 1 h τc = 2 h τc = 5 h τc = 1 h τc = 2 h τc = 5 h
1 197 202 207 103 108 118
2 199 203 207 110 113 121
3 204 216 231 109 112 120
4 231 238 250 96 98 106
5 205 208 214 116 120 129
6 233 243 250 88 90 100
7 194 201 212 95 98 100
8 174 177 182 106 110 121
9 237 243 249 102 111 121
10 241 246 252 115 119 129
mean 212 218 225 104 108 116
±std ±21 ±22 ±23 ±9 ±9 ±10C.1. ROBUSTNESS TEST SINGLE RESULTS 119
C.1 Robustness Test Single results
τc= 1 h
Table C.7: Single meal statistics: percentage of time in which the glucose values
(mg/dl) remain within the indicated ranges. τc= 1 h.The controller output is
increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 81 93 8
2 0 84 93 7
3 0 67 94 6
4 0 77 94 6
5 0 63 87 14
6 0 84 90 10
7 0 90 99 1
8 0 71 100 0
9 0 55 82 18
10 0 57 86 14
mean (±std) 0 73 (±12) 92 (±5) 8 (±5)120 APPENDIX
Table C.8: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated ranges. τc= 1 h. The controller output is
reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 73 84 16
2 0 78 89 11
3 0 55 83 17
4 0 64 88 12
5 0 47 83 18
6 0 73 83 18
7 0 83 91 9
8 0 55 100 0
9 0 43 78 22
10 0 47 82 19
mean (±std) 0 62 (±14) 86 (±6) 14 (±6)
Table C.9: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal. τc= 1 h.
Subject Normal -50% +50%
1 62 49 67
2 62 52 67
3 57 43 70
4 80 67 86
5 63 56 66
6 97 82 107
7 58 45 65
8 23 15 27
9 101 84 107
10 88 75 94
mean 69 76 57
±std ±22 ±23 ±20C.1. ROBUSTNESS TEST SINGLE RESULTS 121
Table C.10: Time to return to the normo-glycemia zone after the meal for τc= 1
h.
Subject Normal -50% +50%
1 7.6 h 6.2 h 8.6 h
2 6.5 5.4 7.2
3 6.6 5.6 7.4
4 4.8 3.1 5.6
5 8.2 6.8 9.2
6 7.1 5.3 8.5
7 4.8 3.7 5.6
8 7.4 4.7 8.0
9 9.0 7.6 10.0
10.0 7.6 8.9 6.0
mean 6.5 7.4 5.1
±std ±1.8 ±2.0 ±1.5
Table C.11: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) values
with τc=1 h.
highest lowest
Subject Normal -50% +50% Normal -50% +50%
1 197 185 203 103 92 110
2 199 189 203 110 103 116
3 204 190 217 109 98 114
4 231 218 237 96 93 100
5 205 199 209 116 107 121
6 233 218 243 88 82 91
7 194 181 201 95 89 99
8 174 166 177 106 95 114
9 237 220 243 102 86 111
10 241 228 247 115 104 121
mean 212 218 199 104 110 95
±std ±21 ±22 ±19 ±9 ±9 ±8122 APPENDIX
τc = 2 h
Table C.12: Single meal statistics: percentage of time that the glucose concen-
tration (mg/dl) remains within the indicated range for τc= 2 h. The controller
output is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 78 87 13
2 0 82 92 8
3 0 65 87 14
4 0 73 93 7
5 0 59 85 15
6 0 81 88 12
7 0 88 96 4
8 0 63 100 0
9 0 50 81 19
10 0 55 85 15
mean (±std) 0 69 (±12) 89 (±5) 11 (±6)
Table C.13: Single meal statistics: percentage of time that the glucose concen-
tration (mg/dl) remains within the indicated range for τc= 2 h. The controller
output is decreased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 70 84 17
2 0 76 89 12
3 0 50 82 18
4 0 55 86 14
5 0 43 82 18
6 0 69 81 20
7 0 81 89 11
8 0 48 97 3
9 0 40 77 23
10 0 43 80 19
mean (±std) 0 58 (±14) 85 (±5) 16 (±5)C.1. ROBUSTNESS TEST SINGLE RESULTS 123
Table C.14: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal. τc= 2 h.
Subject Normal -50% +50%
1 65 54 68
2 66 57 68
3 69 50 80
4 87 73 97
5 66 60 70
6 107 90 110
7 65 52 71
8 27 19 30
9 107 93 112
10 93 82 97
mean 75 80 63
±std ±23 ±23 ±21
Table C.15: Time to return to the normo-glycemia zone after the meal with τc=
2 h.
Subject Normal -50% +50%
1 8.4 h 6.9 h 9.3 h
2 7.1 5.9 7.7
3 7.2 6.0 8.2
4 5.4 4.1 6.4
5 9.0 7.4 10.1
6 8.3 6.1 9.7
7 5.4 4.3 6.3
8 8.0 6.7 8.6
9 9.8 8.2 11.0
10 8.6 6.7 10.1
mean 7.2 8.1 5.8
±std ±1.9 ±2.2 ±1.6
τc = 5 h124 APPENDIX
Table C.16: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) values
for τc = 2 h.
Gmax Gmin
Subject Normal -50% +50% Normal -50% +50%
1 202 191 205 108 98 114
2 203 194 205 113 107 120
3 216 197 227 112 104 119
4 238 224 248 98 95 106
5 208 202 213 120 111 126
6 243 226 246 90 84 95
7 201 187 206 98 93 99
8 177 170 181 110 101 116
9 243 229 247 111 94 117
10 246 235 250 119 109 126
mean 218 223 206 108 114 100
±std ±22 ±23 ±20 ±9 ±10 ± 8
Table C.17: Single meal statistics: percentage of time that the glucose concen-
tration (mg/dl) remains within the indicated range for τc= 5 h. The controller
output is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 74 85 15
2 0 79 90 11
3 0 57 84 16
4 0 65 89 11
5 0 51 83 17
6 0 75 84 16
7 0 84 92 8
8 0 55 100 0
9 0 45 78 22
10 0 49 82 18
mean (±std) 0 63 (±13) 87 (±6) 13 (±6)C.1. ROBUSTNESS TEST SINGLE RESULTS 125
Table C.18: Single meal statistics: percentage of time that the glucose concen-
tration (mg/dl) remains within the indicated range for τc= 5 h. The controller
output is reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 65 82 18
2 0 72 87 13
3 0 43 80 20
4 0 48 82 16
5 0 36 80 20
6 0 60 76 20
7 0 75 86 14
8 0 44 94 7
9 0 34 75 23
10 0 30 78 14
mean (±std) 0 51 (±15) 82 (±5) 17 (±4)
Table C.19: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal. τc= 5 h.
Subject Normal -50% +50%
1 68.4 62.3 70.7
2 69.9 64.9 72.2
3 84.0 66.4 90.8
4 99.2 85.7 100.7
5 71.7 64.6 74.8
6 114.2 104.1 119.7
7 76.7 63.9 80.4
8 31.0 26.3 31.7
9 113.5 105.3 116.0
10 99.3 91.8 101.8
mean 82.8 85.9 73.5
±std ±23.9 ±24.6 ±22.5126 APPENDIX
Table C.20: Time to return to the normo-glycemia zone after the meal for τc= 5
h.
Subject Normal -50% +50%
1 9.8 h 8.2 h 10.8 h
2 8.1 6.9 8.9
3 8.8 7.0 10.1
4 7.1 5.3 8.6
5 10.7 8.8 12.3
6 10.6 7.9 12.2
7 6.8 5.3 7.9
8 9.1 7.8 9.9
9 11.6 9.6 12.8
10 11.4 8.3 14.0
mean 8.7 10.0 7.0
±std ±2.3 ±2.7 ±1.9
Table C.21: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) values
for τc = 5 h.
highest lowest
Subject Normal -50% +50% Normal -50% +50%
1 207 200 209 118 107 124
2 207 202 209 121 112 125
3 231 213 238 120 110 125
4 250 237 252 106 97 111
5 214 207 217 129 120 132
6 250 240 256 100 90 104
7 212 199 216 100 98 111
8 182 177 182 121 108 126
9 249 241 252 121 107 128
mean 225 228 216 116 122 107
±std ±23 ±24 ±22 ±10 ±10 ±9Appendix D
Personalized Model Gains Single
Results
The results for all the subjects with the personalized controller are reported in
this chapter along with the robustness results.
Table D.1: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range for τc = 1 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 84 100 0
2 0 88 100 0
3 0 72 100 0
4 0 78 95 5
5 0 70 96 4
6 9 79 94 6
7 0 92 100 0
8 0 75 100 0
9 24 41 76 11
10 0 67 92 9
mean (±std) 3 (±7) 75 (±13) 95 (±7) 4 (±4)128 APPENDIX
Table D.2: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range for τc = 2 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 82 97 4
2 0 86 96 4
3 0 70 97 3
4 0 75 94 6
5 0 68 94 6
6 6 80 92 8
7 0 90 100 1
8 0 71 100 0
9 20 41 85 16
10 0 63 89 12
mean (±std) 3 (±6) 73 (±13) 94 (±4) 6 (±5)
Table D.3: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range for τc = 3 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 80 92 9
2 0 85 94 6
3 0 68 95 6
4 0 72 93 8
5 0 65 93 8
6 0 85 91 10
7 0 89 97 3
8 0 64 100 0
9 8 50 84 17
10 0 60 87 13
mean (± std) 1 (±2) 72 (±12) 93 (±4) 8 (±5)APPENDIX 129
Table D.4: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range for τc = 4 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 79 88 12
2 0 84 93 7
3 0 66 91 9
4 0 69 92 8
5 0 63 87 13
6 0 84 90 11
7 0 88 96 5
8 0 62 100 0
9 0 56 83 18
10 0 57 86 14
mean (±std) 0 71 (±11) 91 (±5) 10 (±5)
Table D.5: Single meal statistics: percentage of time that the glucose concentration
(mg/dl) remains within the indicated range for τc = 5 h.
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 78 87 14
2 0 83 92 8
3 0 65 87 13
4 0 68 91 10
5 0 62 86 14
6 0 82 89 12
7 0 87 95 6
8 0 60 100 0
9 0 54 82 18
10 0 56 86 15
mean (±std) 0 70 (±11) 90 (±5) 11 (±5)130 APPENDIX
Table D.6: The glucose (mg/dl) peak value relative to the value at tmeal, the meal
time: ∆G = Gmax − Gmeal.
Subject τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
1 50 53 56 50 53
2 40 47 52 40 47
3 30 36 42 30 36
4 65 71 76 65 71
5 44 49 52 44 49
6 65 72 78 65 72
7 41 45 49 41 45
8 10 15 18 10 15
9 56 67 76 56 67
10 56 65 71 56 65
mean 46 52 57 61 64
±std ±16 ±17 ±18 ±19 ±19
Table D.7: Time to return to the normo-glycemia zone after the meal for diﬀerent
τc values
Subject τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
1 5.4 h 5.9 h 6.3 h 6.7 h 7.0 h
2 4.4 4.9 5.2 5.5 5.8
3 4.8 5.2 5.5 5.8 6.0
4 2.9 3.6 4.3 4.6 5.0
5 5.4 5.9 6.3 6.6 6.9
6 4.1 4.6 5.1 5.4 5.8
7 3.3 3.7 4.1 4.4 4.7
8 3.7 4.6 6.4 6.8 7.2
9 6.2 6.7 7.1 7.5 7.8
10 4.8 5.3 5.7 6.0 6.3
mean 4.2 4.7 5.2 5.5 5.8
±std ±1.2 ±1.3 ±1.4 ±1.4 ±1.5APPENDIX 131
Table D.8: Blood Glucose (mg/dl) maximum values.
Subject τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
1 179 183 185 190 193
2 176 183 188 190 193
3 177 183 189 192 196
4 216 222 227 230 233
5 186 192 195 198 200
6 201 208 214 219 222
7 176 180 185 189 192
8 160 166 169 170 173
9 192 203 212 218 223
10 209 217 223 228 231
mean 187 194 199 202 199
±std ±16 ±17 ±18 ±19 ±18
Table D.9: Blood Glucose (mg/dl) maximum values.
Subject τc = 1 h τc = 2 h τc = 3 h τc = 4 h τc = 5 h
1 83 88 93 96 99
2 97 100 112 104 106
3 87 93 97 101 104
4 93 94 96 96 97
5 93 99 103 106 108
6 74 79 81 83 84
7 85 89 91 93 95
8 90 94 99 102 105
9 64 72 79 84 89
10 88 95 100 104 106
mean 85 90 94 94 94
±std ±9 ±8 ±8 ±8 ±8132 APPENDIX
D.1 Robustness Test Single Results
τc = 2 h
Table D.10: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 2 h. The controller output
is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 11 74 100 0
2 0 89 100 0
3 0 79 100 0
4 0 80 96 5
5 0 73 100 0
6 9 81 93 5
7 0 93 100 0
8 0 79 100 0
9 14 45 80 3
10 0 70 94 6
mean (±std) 3 (±5) 76 (±12) 96 (±6) 2 (±2)D.1. ROBUSTNESS TEST SINGLE RESULTS 133
Table D.11: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 2 h.The controller output
is reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 79 89 11
2 0 84 93 7
3 0 67 92 8
4 0 70 92 8
5 0 64 87 13
6 0 84 90 10
7 0 88 96 4
8 0 62 100 0
9 0 57 83 17
10 0 58 87 14
mean (±std) 0 71 (±11) 91 (±5) 9 (±5)
Table D.12: The glucose (mg/dl) peak value relative to the value at tmeal, the
meal time: ∆G =Gmax-Gmeal. τc = 2 h.
Subject Normal -50% +50%
1 51 42 57
2 46 34 53
3 36 25 45
4 71 61 79
5 49 37 55
6 72 59 82
7 45 38 52
8 15 4 19
9 67 49 81
10 65 47 74
mean 52 60 40
±std ±17 ±19 ±16134 APPENDIX
Table D.13: Time to return to the normo-glycemia zone after the meal. τc = 2 h.
Subject Normal -50% +50%
1 5.9 h 4.9 h 6.6 h
2 4.9 4.0 5.4
3 5.2 3.0 5.7
4 3.6 2.5 4.6
5 5.9 4.8 6.6
6 4.6 3.7 5.3
7 3.7 2.9 4.3
8 4.6 3.0 6.8
9 6.7 5.7 7.4
10 5.3 4.4 5.9
mean 4.7 5.5 3.6
±std ±1.3 ±1.4 ±1.2
Table D.14: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) glu-
cose values during the post-prandial response. τc = 2 h.
highest lowest
Subject Normal -50% +50% Normal -50% +50%
1 183 174 189 88 77 95
2 183 170 190 100 95 103
3 183 172 192 93 84 100
4 222 212 230 94 94 96
5 192 180 197 99 87 106
6 208 195 218 79 69 82
7 180 173 188 89 81 93
8 166 155 170 95 87 102
9 203 185 217 72 56 83
10 217 200 227 95 80 103
mean 194 202 182 90 96 81
±std ±17 ±19 ±16 ±8 ±8 ±11D.1. ROBUSTNESS TEST SINGLE RESULTS 135
τc = 3 h
Table D.15: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 3 h. The controller output
is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 84 100 0
2 0 88 100 0
3 0 75 100 0
4 0 79 95 5
5 0 71 97 3
6 10 80 94 6
7 0 92 100 0
8 0 77 100 0
9 24 42 77 8
10 0 68 93 8
mean (±std) 3 (±7) 76 (±13) 96 (±7) 3 (±3)
Table D.16: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 3 h. The controller output
is reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
0 78 87 14
2 0 83 92 8
3 0 65 87 14
4 0 67 90 10
5 0 61 86 14
6 0 82 88 12
7 0 86 94 6
8 0 60 100 0
9 0 53 82 19
10 0 55 85 15
mean (±std) 0 69 (±12) 89 (±5) 11 (±5)136 APPENDIX
Table D.17: The glucose (mg/dl) peak value relative to the value at tmeal, the
meal time: ∆G = Gmax − Gmeal. τc = 3 h.
Subject Normal -50% +50%
1 52 44 60
2 51 38 57
3 42 28 50
4 76 63 84
5 52 41 58
6 78 63 87
7 49 39 57
8 18 8 22
9 76 54 89
10 71 53 79
mean 57 64 43
±std ±18 ±20 ±16
Table D.18: Time to return to the normo-glycemia zone after the meal. τc = 3 h.
Subject Normal -50% +50%
1 6.3 h 5.2 h 7.1 h
2 5.2 4.3 5.8
3 5.5 3.5 6.0
4 4.3 2.8 5.0
5 6.3 5.2 7.0
6 5.1 4.0 5.9
7 4.1 3.1 4.7
8 6.4 3.5 7.2
9 7.1 6.0 7.9
10 5.7 4.7 6.4
mean 5.2 5.9 3.9
±std ±1.4 ±1.5 ±1.2D.1. ROBUSTNESS TEST SINGLE RESULTS 137
Table D.19: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) glu-
cose values during the post-prandial response . τc = 3 h.
highest lowest
Subject Normal -50% +50% Normal -50% +50%
1 185 177 193 93 81 100
2 188 174 194 102 96 106
3 189 175 197 97 86 104
4 227 214 235 96 93 97
5 195 184 200 103 91 109
6 214 199 223 81 73 84
7 185 175 193 92 84 95
8 169 159 173 99 89 105
9 212 190 224 79 61 90
10 223 206 232 100 85 107
mean 199 207 185 94 100 84
±std ±18 ±19 ±16 ±8 ±8 ±10138 APPENDIX
τc=4 h
Table D.20: Single meal statistics: percentage of time that the glucose concen-
tration (mg/dl) remains within the indicated range for τc = 4 h. The controller
output is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 83 99 1
2 0 87 100 0
3 0 71 100 0
4 0 77 95 6
5 0 70 96 4
6 9 79 93 7
7 0 92 100 0
8 0 75 100 0
9 23 40 75 14
10 0 66 91 9
mean (±std) 3 (±7) 74 (±14) 95 (±7) 4 (±5)
Table D.21: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 4 h. The controller output
is reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 76 86 14
2 0 81 91 9
3 0 62 86 14
4 0 64 88 12
5 0 59 85 15
6 0 80 87 13
7 0 85 93 8
8 0 57 100 0
9 0 49 81 19
10 0 54 85 16
mean (±std) 0 67 (±12) 88 (±5) 12(±5)D.1. ROBUSTNESS TEST SINGLE RESULTS 139
Table D.22: The glucose (mg/dl) peak value relative to the value at tmeal, the
meal time: ∆G = Gmax − Gmeal. τc = 4 h.
Subject Normal -50% +50%
1 55 46 62
2 54 41 60
3 45 32 54
4 79 66 86
5 55 45 60
6 83 67 94
7 53 44 63
8 20 11 24
9 82 57 94
10 75 58 83
mean 60 68 46
±std ±19 ±20 ±16
Table D.23: Time to return to the normo-glycemia zone after the meal. τc = 4 h.
Subject Normal -50% +50%
1 6.7 h 5.5 h 7.5 h
2 5.5 4.5 6.2
3 5.8 4.9 6.3
4 4.6 3.1 5.5
5 6.6 5.5 7.4
6 5.4 4.2 6.4
7 4.4 3.3 5.0
8 6.8 3.9 7.6
9 7.5 6.3 8.3
10 6.0 4.9 6.8
mean 5.5 6.3 4.3
±std ±1.4 ±1.6 ±1.2140 APPENDIX
Table D.24: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) glu-
cose values during the post-prandial response. τc = 4 h.
Gmax Gmin
Subject Normal -50% +50% Normal -50% +50%
1 190 180 197 96 84 102
2 190 178 197 104 97 108
3 192 179 201 101 89 107
4 230 217 237 96 93 99
5 198 188 203 106 94 111
6 219 203 230 83 76 85
7 189 177 198 93 86 97
8 170 162 175 102 91 107
9 218 193 229 84 66 95
10 228 211 236 103 89 109
mean 202 210 189 97 102 87
±std ±19 ±20 ±16 ±8 ±8 ±9τc = 5 h
Table D.25: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 5 h. The controller output
is increased of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 82 97 3
2 0 87 97 3
3 0 70 98 2
4 0 76 94 6
5 0 68 95 6
6 8 80 93 8
7 0 91 100 0
8 0 73 100 0
9 22 40 85 15
10 0 64 89 11
mean (±std) 3 (±7) 73 (±14) 95 (±5) 5 (±5)
Table D.26: Single meal statistics: percentage of time that the glucose concentra-
tion (mg/dl) remains within the indicated range. τc = 5 h. The controller output
is reduced of the 50%
Subject 60<G<80 80<G<140 70<G<180 180<G<250
1 0 75 85 15
2 0 80 91 10
3 0 60 85 15
4 0 63 87 13
5 0 57 85 16
6 0 78 86 14
7 0 84 92 8
8 0 55 100 0
9 0 48 80 20
10 0 53 84 16
mean (±std) 0 65 (±12) 88 (±5) 13 (±5)142 APPENDIX
Table D.27: The glucose (mg/dl) peak value relative to the value at tmeal, the
meal time: ∆G = Gmax − Gmeal. τc = 5 h.
Subject Normal -50% +50%
1 58 47 64
2 57 45 62
3 49 35 58
4 83 69 90
5 57 48 61
6 87 70 96
7 56 43 64
8 22 13 26
9 87 64 97
10 78 62 86
mean 64 71 50
±std ±19 ±21 ±17
Table D.28: Time to return to the normo-glycemia zone after the meal. τc = 5 h.
Subject Normal -50% +50%
1 7.0 h 5.8 h 7.9 h
2 5.8 4.8 6.4
3 6.0 5.1 6.6
4 5.0 3.3 5.9
5 6.9 5.8 7.8
6 5.8 4.5 6.9
7 4.7 3.6 5.4
8 7.2 4.3 7.9
9 7.8 6.6 8.6
10 6.3 5.1 7.3
mean 5.8 6.6 4.6
±std ±1.5 ±1.6 ±1.3D.1. ROBUSTNESS TEST SINGLE RESULTS 143
Table D.29: Blood Glucose (mg/dl) maximum (Gmax) and minimum (Gmin) glu-
cose values during the post-prandial response. τc = 5 h.
Gmax Gmin
Subject Normal -50% +50% Normal -50% +50%
1 193 182 199 99 87 106
2 193 181 199 106 99 110
3 196 182 205 104 91 109
4 233 220 241 97 94 103
5 200 190 204 108 97 114
6 222 206 232 84 78 87
7 192 179 200 95 88 98
8 173 164 177 105 93 109
9 223 199 233 89 70 99
10 231 216 239 106 93 112
mean 206 213 192 99 105 89
±std ±19 ±21 ±17 ±8 ±8 ±8144 APPENDIXBibliography
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